Document:

exv10w73

Exhibit 10.73

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

MASTER MANUFACTURING AGREEMENT

     This MASTER MANUFACTURING AGREEMENT (the “Agreement”) effective as of March 20, 2008 (the
“Effective Date”) is by and between Medicis Global Services Corporation, a Delaware corporation,
having offices at 8125 North Hayden Road, Scottsdale, AZ, 85258 (hereinafter “Medicis”), and
WellSpring Pharmaceutical Canada Corp., having offices at 400 Iroquois Shore Road, Oakville, ON L6H
1M5, Canada (hereinafter “Supplier”). Medicis and Supplier are sometimes referred to herein
individually as a “Party” and collectively as the “Parties.”

RECITALS

     WHEREAS, Supplier is in the business of providing contract manufacturing, supply, packaging
and other related services; and

     WHEREAS, Medicis desires to utilize the contract manufacturing, supply, packaging or other
related services of Supplier from time to time pursuant to the terms and conditions of this
Agreement, and Supplier desires to provide such services to Medicis in accordance with the terms
and conditions of this Agreement.

     NOW THEREFORE, in consideration of the above premises and subject to the terms and conditions
stated herein, the Parties agree as follows:

ARTICLE 1

INTERPRETATION

1.1 Definitions. Capitalized terms used in this Agreement shall have the meanings ascribed
to them in Schedule 1.1 (Definitions) or in the context in which they are used and herein. All
defined terms include the plural as well as the singular.

1.2 Sections and Headings. The division of this Agreement into Articles, Sections,
subsections and Schedules and the insertion of headings are for convenience of reference only and
shall not affect the interpretation of this Agreement. Unless otherwise indicated, any reference
in this Agreement to a Section or Schedule refers to the specified Section or Schedule to this
Agreement. In this Agreement, the terms “this Agreement,” “hereof,” “herein,” “hereunder” and
similar expressions refer to this Agreement, inclusive of all Schedules, Exhibits and other
documents incorporated by reference, and not to any particular part, Section, Schedule or the
provision hereof.

1.3 Conflicts in Interpretation. In the event of any conflict between the terms and
conditions of the Agreement, the Quality Agreement and the applicable Product Exhibit, unless
otherwise expressly stated, the following shall be the order of precedence: (a) Agreement; (b)
Quality Agreement; and (c) Product Exhibit, except for all matters pertaining to, or governed by,
GMPs, the provisions of the Quality Agreement will prevail.

ARTICLE 2

MANUFACTURE AND SUPPLY OF PRODUCTS

2.1 Manufacture.

(a) Supplier shall Manufacture and sell to Medicis the Product in accordance with the terms
and conditions of this Agreement, the Quality Agreement and the applicable Product Exhibit.
Medicis or its Affiliates shall have the right to: (i) license to a Third Party the right
to distribute, sell or market Product; and (ii) order Product under this Agreement for the
benefit of such Third Party. In such an event, Supplier shall fulfill such orders in
accordance with the terms and conditions of this Agreement, the Quality Agreement and the
applicable Product Exhibit.

Medicis / Wellspring — Master Manufacturing Agreement

Page 1 of 24

 

(b) Supplier shall not Manufacture a Product, or any portion of a Product, in any facility
other than the Facility without Medicis prior written approval. Supplier shall not make any
material change to the manufacturing equipment or manufacturing process of the Products
without Medicis’s prior written approval. The Product shall not contain reworked or
reprocessed materials without Medicis’s prior written approval. Any rework process shall be
approved in the applicable NDA.

2.2 Product and Product Exhibits. Each Product Exhibit will include the following, if
applicable: (a) description of the Services; (b) description of the start and completion dates for
the Services and any other interim milestones; (c) description of the Medicis-Supplied Material and
the Medicis-Supplied Material Specifications; (d) Minimum Yield for the Product; (e) NDA for the
Product, if applicable; (f) Price for the Product; (g) Specifications for the Product; and (h)
minimum batch size to be ordered for each Product as set forth in the applicable Product Exhibit.
Each Product Exhibit will be in the form set forth as Exhibit A.

2.3 Components. Unless otherwise set forth in a Product Exhibit, at Supplier’s expense,
Supplier shall: (a) provide all Components; and (b) test and verify that all Components meet the
Specifications.

2.4 Medicis-Supplied Material.

2.4.1 Delivery. At Medicis’s sole cost and expense, Medicis shall use its
commercially reasonable efforts to deliver the Medicis-Supplied Material to Supplier in the
quantities sufficient to meet Medicis’s forecasted requirements. Supplier shall use the
Medicis-Supplied Material only to perform the Services.

2.4.2 Damage/Discrepancies. Within five (5) Business Days following Supplier’s
receipt of the Medicis-Supplied Material, Supplier shall inform Medicis of any damage to the
Medicis-Supplied Material received that is visually obvious (e.g., damaged or punctured
containers) and/or discrepancies in quantity received. Supplier will perform an analytical
testing on the Medicis-Supplied Material in accordance with the Quality Agreement, informing
Medicis within *** of any failure to conform to the Specifications of the Medicis-Supplied
Material. In the event such deficiency in the Medicis-Supplied Material causes Supplier to
fail to meet its obligations under this Agreement, Supplier shall be excused from
performance to the extent Supplier did not cause such deficiency and such deficiency
adversely affects Supplier’s performance under this Agreement.

2.4.3 Risk of Loss. Risk of loss, damage, or contamination of the Medicis-Supplied
Material shall pass to Supplier upon delivery. If any Medicis-Supplied Material,
non-processing losses, work in process or Product is destroyed, damaged or lost while risk
of loss lies with Supplier, Supplier shall reimburse Medicis for the amount of such lost,
destroyed or damaged Medicis-Supplied Material at the Reimbursement Value. Supplier shall
reimburse Medicis within *** after determining the root cause for the loss or, at Medicis’s
option, Medicis shall set off the Reimbursement Value against invoices that Medicis owes
Supplier, or against future invoices related to the Product. If Medicis receives the
Reimbursement Value from Supplier, then such destroyed, damaged or lost Medicis-Supplied
Material shall not be included in the calculation of Yield.

2.4.4 Title. Medicis shall at all times retain title to the Medicis-Supplied
Material. Supplier shall keep Medicis’s title to all Medicis-Supplied Material free and
clear of all liens and encumbrances and, if Supplier fails to keep Medicis’s title to all
Medicis-Supplied Material free and clear of all liens and encumbrances, then Supplier shall
pay all costs associated with securing the release of any such liens and encumbrances and
shall indemnify Medicis for all Claims incurred by Medicis as a result of Supplier’s breach
of this Section. If requested by Medicis, the Parties agree to discuss in good faith
entering into a mutually acceptable consignment agreement (or similar document) with respect
to Medicis-Supplied Material delivered to Supplier by Medicis or its supplier.

Medicis / Wellspring — Master Manufacturing Agreement

Page 2 of 24

 

2.4.5 Inventory Report of Medicis-Supplied Material. Within five (5) Business
Days following the end of each calendar month, Supplier shall inform Medicis in writing of
the quantities of Medicis-Supplied Material remaining in Supplier’s Inventory.

2.5 Packaging, Labeling and Lot Numbers/Expiration Dates.

(a) Supplier shall include Labeling on or with the Product only as specified by Medicis and
with the prior written approval of Medicis. At any time, in its sole discretion and with
prior written notice to Supplier, Medicis shall have the right to make changes to the
Labeling for the Products, which changes Medicis shall submit to all applicable governmental
agencies and other Third Parties responsible for the approval of the Products, if required.
Supplier’s name shall not appear on the Labeling or Products unless required by a
governmental agency or other Applicable Laws.

(b) Supplier shall arrange and implement the imprinting of lot numbers and expiration dates
for each Product shipped. Such lot numbers and expiration dates shall be affixed on the
Products and on the shipping carton of each Product as required by cGMPs.

2.6 Special Equipment. Supplier shall purchase any non-standard or special equipment,
including without limitation instrumentation or process equipment, required for the performance of
Services (“Special Equipment”) only with Medicis’s prior written approval. The Price or Fees, as
applicable, shall include Special Equipment unless the Parties agree in writing that Medicis shall
reimburse Supplier for the Special Equipment, in which case such reimbursement shall be made only
on a pass-through basis. Title to Special Equipment shall remain vested in Supplier until it is
assigned to Medicis except in the case where Special Equipment is purchased directly in Medicis’s
name. In addition, Medicis shall have the right to have title to any Special Equipment purchased
hereunder in the name of Medicis. Risk of damage or loss to Special Equipment shall remain with
Supplier for as long as Supplier possesses the Special Equipment. Upon expiration and non-renewal
or termination of the applicable Services or as otherwise requested by Medicis, Supplier shall
assign the ownership of Special Equipment to Medicis pursuant to a bill of sale transferring title
free of any liens or encumbrances. If applicable, all Special Equipment transferred to Medicis
shall include the original manufacturer’s warranty, to the extent it is assignable to Medicis.
Supplier shall not purchase Special Equipment with warranties or maintenance programs that are not
assignable to Medicis without Medicis’s prior written consent.

2.7 Supplier Relationship Team. Within a reasonable period of time following the Effective
Date, Supplier and Medicis shall form a team to address issues and oversee the relationship between
Medicis and Supplier with at least one (1) representative from each Party (“Supplier Relationship
Team”). Both Parties shall cooperate to identify for the Supplier Relationship Team and, with both
Parties approval, pursue projects that will improve the manufacturing processes and reduce the
costs for Product. The Parties shall share any cost savings to the Manufacture of Product realized
as a result of the work of the Supplier Relationship Team and the applicable Price shall be
adjusted accordingly to reflect such cost savings and sharing. Upon mutual written consent of the
Parties, the Parties may invite, at their own expense, internal or external consultants to advise
the Supplier Relationship Team. Any and all such external consultants shall execute a
confidentiality agreement in a form mutually acceptable to the Parties.

2.8 Subcontracting. Supplier shall not utilize any subcontractors (including any Affiliate
of Supplier) to provide any part of the Services without the prior written approval of Medicis.

2.9 Medicis Responsibilities. References to Medicis’s responsibilities in this Agreement
or any Product Exhibit (other than Medicis’s promise to pay for the Services), are intended solely
for purposes of identifying what is not Supplier’s responsibility and will not under any
circumstance constitute grounds for a claim that Medicis has breached this Agreement.

2.10 Consents and Approvals. For the avoidance of doubt, all actions requiring the
approval or consent of a Party under this Agreement must be approved or consented to in writing.

Medicis / Wellspring — Master Manufacturing Agreement

 Page 3 of 24

 

ARTICLE 3

ORDERS, DELIVERY AND CAPACITY

3.1 Forecast. Prior to the end of each calendar month, Medicis shall provide to Supplier a
forecast of the estimated quantities of the Product for the immediately succeeding *** (the
“Forecast”). Medicis shall purchase the quantity of Product identified in the Forecast for the ***
(“Firm Order”). The quantity of Product for the *** of the Forecast shall be considered
non-binding. If requested by Medicis, Supplier shall exercise commercially reasonable efforts to
deliver at least *** of the quantity of Product in the applicable Forecast. Except as set forth in
this Agreement or the applicable Product Exhibit, Medicis makes no guarantee with respect to the
quantity of Product that may be purchased from Supplier by Medicis or its Affiliates.

3.2 Written Orders. Each Firm Order shall specify Medicis’s purchase order number,
quantities, monthly delivery schedule and any other elements necessary to ensure the timely
production and delivery of the Products. Medicis shall have the right to postpone the delivery
dates for Products ordered for delivery during the *** of such Firm Order if a request is made
prior to the *** following the *** of such Firm Order. If Medicis postpones delivery of Firm
Orders, at the end of *** following the original delivery date, Medicis will ***. Medicis shall
receive a credit from Supplier for any such Inventory subsequently used in the production of
Products. Upon mutual written agreement, the Parties may decrease the quantities for the *** of
such Firm Order.

3.3 Batch Acceptance/Release.

(a) The Products to be Manufactured by Supplier may only be ordered in the minimum batch
sizes set forth in the Product Exhibit, except that, if applicable, Medicis may designate
split batch filling, provided that the Parties shall have agreed in advance to any increased
cost of split batch filling.

(b) Supplier shall perform all applicable in-process testing in accordance with the
Specifications using validated methods prior to releasing Product to Medicis. No less than
five (5) Business Days prior to the requested shipment date in the applicable Firm Order,
Supplier shall provide Medicis, for Medicis’s written approval for final release, a batch
release document package consisting of: (i) copies of Labeling; (ii) applicable sections of
batch records or upon Medicis’s request a complete copy of the batch record; (iii) a copy of
all deviations/investigations, if any; (iv) a certificate of analysis; and (v) a certificate
of conformance provided by Supplier’s quality control manager attesting to the fact that the
Products have been Manufactured in accordance with the Specifications and Manufacturing
Requirements (collectively, “Release Information”).

(c) Medicis shall have *** after receipt of the Release Information to notify Supplier in
writing whether it agrees that the Product can be released for shipment. In the event of a
denial, Medicis shall send to Supplier a Deficiency Notice as set forth in Section 3.4
below. Within *** after receiving Medicis’s written release to ship, Supplier shall ship
the Product to Medicis, or to any other destination designated by Medicis. Shipment by
Supplier shall be ***.

3.4 Non-Conforming Orders.

3.4.1 Notification. Medicis shall send to Supplier any Deficiency Notice
within *** after receipt of the Product. In the event a Defect in the Product could not
reasonably be discovered within this *** period (“Latent Defect”), Medicis shall have the
right to reject such Product within *** after discovering the
Latent Defect. Except as set out in this Section 3.4 and Section 4.9 (Product Returns) and
4.10 (Product Recalls), ***. Upon receipt of a Deficiency Notice, Supplier shall have ***
to notify Medicis in writing as to whether it agrees that the subject Product deviates from
the Specifications. If Medicis and Supplier fail to agree within *** following Supplier’s
notice to Medicis, the Parties shall resolve the dispute pursuant to Section 3.4.3.
Supplier shall, at its sole cost and expense: (a) use commercially reasonable efforts to
replace the rejected Product with Product that is not Defective as soon as reasonably
practicable, but in no event longer than *** of completion of the investigation of the
Defect contingent upon receipt of all Medicis-Supplied Material; (b) ship such replacement
Product in accordance with Section 3.3(c); and (c) reimburse to Medicis the Reimbursement
Value the Medicis-Supplied Material incorporated into the

Medicis / Wellspring — Master Manufacturing Agreement

Page 4 of 24

 

Defective Product. If both Parties decide that the Product cannot be reworked or used, Supplier shall arrange, at its
sole cost and expense, for all such Defective Product to be picked up and destroyed in
accordance with all Applicable Laws and deliver to Medicis a certificate of destruction
signed by an authorized representative of Supplier. Subject to the provisions of this
Section, Medicis has the right to reject and return, at the expense of Supplier and for full
credit, any portion of any shipment which deviates from the Specifications, without
invalidating the remainder of the order.

3.4.2 Shortages. If the Yield for any batch of Product is less than *** of the
batch size as set out in any Firm Order (“Acceptable Yield”), then Supplier shall reimburse
Medicis for the Medicis-Supplied Material theoretically contained in the shortfall. The
amount of Medicis-Supplied Materials theoretically contained in the Shortfall shall be
calculated in accordance with the master batch record for such Product. Supplier shall
reimburse Medicis for the Medicis-Supplied Materials at Medicis’s actual replacement cost at
the time of replacement of the Medicis-Supplied Material (“Medicis-Supplied Material
Reimbursement Value”). Upon the written request of Supplier, Medicis shall support the
Medicis-Supplied Material Reimbursement Value by providing such documentation that Medicis
has in its possession or reasonable control. Notwithstanding the foregoing, Medicis, in its
discretion, shall have the right to use the Medicis-Supplied Material Reimbursement Value to
set-off against future orders or any other undisputed fees or costs owed to the Supplier.
To allow the Supplier to establish a consistent yield track record, the requirement to
reimburse the Medicis-Supplied Material Reimbursement Value will not apply for registration
batches or for the *** including the validation batches on a Product strength by Product
strength basis.

3.4.3 Third-Party Testing. In the event Supplier does not agree with Medicis’s
determination that the Product is Defective, the Parties shall attempt, in good faith, to
resolve such dispute. If Medicis and Supplier cannot resolve such dispute, an independent
laboratory that is acceptable to both Parties shall be asked to test the Product in dispute
(“Disputed Product”). To the extent such laboratory finds that the Disputed Product is not
Defective, Medicis shall pay the fees of such laboratory related to such testing and shall
promptly pay for the Disputed Product. To the extent that such laboratory finds that the
Disputed Product is Defective, Supplier shall pay the fees of such laboratory related to
such testing.

3.5 Capacity.

(a) At all times during the Term of this Agreement, Supplier shall have sufficient capacity
to meet Medicis’s requirements with respect to the Products. To the extent necessary to
manufacture the Products, Supplier shall notify Medicis in writing of any additional costs
of dedicated equipment or space. If Medicis approves of such costs, Medicis shall have the
right to reimburse Supplier for such costs; provided that if Medicis reimburses Supplier for
such costs, then upon the expiration and non-renewal or termination of this Agreement for
any reason, at Medicis’s request, Supplier shall assign, convey, transfer and deliver such
equipment to a facility of Medicis or its designee.

(b) During the Term, Supplier shall be responsible for supplying qualification documentation
for inclusion in any applicable regulatory filings in the United States for any Product
manufactured by Supplier under this Agreement and for the regulatory submission and approval
of the Facility. Supplier shall
maintain the applicable Facility in a production capable and ready state throughout the Term
of this Agreement.

(c) Within *** following receipt of a Forecast, Supplier shall confirm to Medicis in writing
in a form similar in form and substance to Exhibit C that it has the manufacturing capacity
to deliver the forecasted volumes.

ARTICLE 4

QUALITY CONTROL AND COMPLIANCE

4.1 Quality Agreement. The Quality Agreement shall be agreed upon by the Parties prior to
initiation of the process validation batches and attached as Exhibit B to this Agreement.

Medicis / Wellspring — Master Manufacturing Agreement

Page 5 of 24

 

4.2 Quality Control and Assurance.

	 	(a)	 	Supplier shall perform the Services and perform quality assurance and quality
control testing in accordance with: (i) the applicable NDA and/or regulatory approval
including, without limitation, the detailed chemistry manufacturing control section
thereof; (ii) the applicable Specifications; (iii) the cGMPs; (iv) all other Applicable
Laws; and (v) the mutually approved batch record.
	 
	 	(b)	 	Supplier shall ensure the Products delivered under this Agreement will not be
adulterated or misbranded by Supplier under the Federal Food, Drug and Cosmetic Act
(“Act”), or under any other Applicable Laws.
	 
	 	(c)	 	Supplier shall perform such quality control and quality assurance testing as is
reasonably required to ensure that the Products comply with all of the Manufacturing
Requirements.

4.3 Product Change.

4.3.1 Change Control. Supplier and Medicis shall have formal procedures to document
all changes relating to a Product, including changes that: (a) impact the regulatory
approvals for the Product; (b) may affect the quality, purity, safety, identity or strength
of the Medicis-Supplied Material or the Product; or (c) may require re-validation of any
part of the Services or Manufacturing process. All proposed changes shall be communicated
in writing and are subject to Medicis’s prior written approval.

4.3.2 Change in Specifications.

(a) Medicis shall have the right upon written notice to Supplier to request Supplier to
institute a change in the Specifications for a Product. Supplier shall respond in writing
within *** whether Supplier is capable of instituting the change in the Specifications
requested by Medicis, the time frame necessary to implement that change, and what effect, if
any, Supplier believes such change will have on the Price for such Product.

(b) If Supplier indicates that it is not capable of implementing such change and the change
is required by a governmental agency or Applicable Law, the inability of Supplier shall be
deemed a Force Majeure. If Supplier indicates it is capable of implementing such change,
the Parties shall in good faith agree on the date for implementation of the change and what
increase or decrease, if any, in the applicable Price.

4.4 Validation and Testing.

(a) Medicis shall review and approve in writing all validation protocols, results and
reports of the validation activities relating to the Product.

(b) Supplier shall test the integrity of the packaging for the Product in accordance with
protocols approved by Medicis. Such test will be at Medicis’s cost and expense for
validation batches, and at Supplier’s cost and expense for batches for commercial
production. In the event a failure in the packaging is identified, Supplier and Medicis
shall jointly investigate the causes of such failure, including which Party shall bear the
cost of such investigation. Upon request, Supplier shall provide to Medicis any and all
data and results in its possession relating to such testing.

(c) In accordance with the applicable Product Exhibit or protocols as designated by Medicis,
Supplier, Medicis or a designated Third Party shall conduct stability tests on the Product.
In the event that any lot of Product fails stability testing, Supplier and Medicis shall
jointly investigate the causes of such failure, including which Party shall bear the cost of
such investigation. Upon request, Supplier shall provide to Medicis any and all data and
results in its possession relating to the stability testing.

4.5 Product and Process Qualification. Medicis and Supplier will mutually agree upon the
requirements and the degree of product and process qualifications. All qualification procedures
and results shall require Medicis’s

Medicis / Wellspring — Master Manufacturing Agreement

Page 6 of 24

 

prior written approval. Supplier shall qualify all: (a)
equipment, computer, utilities, and facilities relating to a Product; and (b) processes used in
providing Services, assuring that the process is capable of consistently achieving the acceptance
criteria of the process qualification and Specifications. Medicis and Supplier will work together
to resolve any process capability issues.

4.6 Safety.

4.6.1 Material Safety Data Sheet. Medicis shall provide Supplier with Material
Safety Data Sheets, and updates thereof, for Medicis-Supplied Material as required by
Applicable Law. Each Party shall comply with any exposure requirements for Medicis-Supplied
Material. Supplier shall promptly inform Medicis of any known adverse environmental,
health, or safety events related to the Manufacture of Product

4.6.2 Product Safety. Supplier shall inform Medicis in writing of any major
deviations that can potentially impact the Product’s safety, identity, strength, quality or
purity, and shall provide supporting documentation.

4.6.3 Waste Disposal. Supplier shall collect and dispose of all waste generated in
the performance of the Services in accordance with all Applicable Laws.

4.7 Personnel Training/Qualification. All Supplier personnel engaged in providing Services
shall have the appropriate education, training and experience required to perform their assigned
functions properly. Supplier shall have a documented training program for such personnel.

4.8 Customer Questions, Complaints and Product Inquiries.

(a) Medicis shall have the sole responsibility for responding to questions and complaints
from Medicis customers. Questions or complaints received by Supplier from Medicis customers
shall be referred to Medicis within ***. Medicis shall evaluate and, if necessary and as
reasonably required, request Supplier’s support in its investigation.

(b) Medicis shall receive all Product inquiries including quality complaints, adverse drug
reactions and requests for medical information (an “Inquiry”). Supplier shall notify
Medicis within *** of any receipt of an Inquiry and immediately forward it to Medicis.
Medicis shall evaluate and, if necessary and as reasonably required, request Supplier’s
support in its investigation.

4.9 Product Returns. Medicis shall have the responsibility for handling customer returns
of the Products and Supplier shall provide reasonable assistance to Medicis for handling such
returns. To the extent that such return results from, or arises out of, any Defect, Supplier
shall: (a) use commercially reasonable efforts to replace the returned Products with new Products
as soon as reasonably practicable, but in no event longer than sixty (60) calendar days from the
date that Medicis notifies Supplier about the returned Products, contingent upon the receipt or
availability from Medicis of all Medicis-Supplied Material; and (b) Supplier shall reimburse
Medicis for the sum of (A) Medicis-Supplied Material Reimbursement Value, (B) the Price paid by
Medicis for the recalled Product, and (C) Medicis’s reasonable out-of-pocket expenses for
retrieval, transportation and destruction of the returned Product, including reasonable
administrative expenses.

4.10 Product Recalls.

(a) Supplier and Medicis shall maintain records necessary to permit a recall or a field
correction of any of the Products delivered to Medicis or customers of Medicis, affected
voluntarily or under a threat of, or a directive by, any governmental agency. Each Party
shall give immediate notice by telephone (with written confirmation) to the Director of
Quality Control or Quality Assurance of the other Party that any Products should be recalled
or corrected, or may be required to be recalled or corrected. Medicis shall decide to
initiate a recall or to take some other corrective action, if any. Medicis shall control
such recall or corrective action, and Supplier will co-operate as reasonably required.

Medicis / Wellspring — Master Manufacturing Agreement

Page 7 of 24

 

(b) To the extent that a recall results from, or arises out of, a Defect then: (i)
such recall shall be made at Supplier’s cost and expense, including without limitation, that
Supplier shall reimburse Medicis for the sum of (A) Medicis-Supplied Material Reimbursement
Value, (B) the Price for the recalled Product, and (C) Medicis’s reasonable out-of-pocket
expenses for retrieval, transportation and destruction of the recalled Product; and (ii) if
requested by Medicis, Supplier shall use its commercially reasonable efforts to replace the
recalled Products with new Products as soon as reasonably practicable, but in no event
longer than *** from the date that Medicis notifies Supplier about the recalled Products,
contingent upon the receipt or availability from Medicis of all Medicis-Supplied Material.

4.11 Retention and Record Keeping.

(a) Supplier shall retain and store in a secure manner representative samples from each
Product lot: (i) as required by the United States Code of Federal Regulations (“CFR”); and
(ii) in no event, for at least *** after the Product’s expiration date. Supplier shall
retain Component representative samples for at least ***. Supplier will notify Medicis
prior to retained sample destruction and upon Medicis’s request, shall provide the samples
to Medicis at Medicis’s expense.

(b) Supplier shall keep records of the Manufacture of the Products, and retain samples of
such Products that are necessary to comply with applicable regulations, including the
requirements of the United States Code of Federal Regulations (“CFR”) as well as to assist
with resolving Product complaints and other similar investigations. Copies of such records
and samples shall be made available to Medicis upon its request and shall be retained by
Supplier and be available to Medicis for a period of *** following the Product’s expiration
date, or longer if required by Applicable Law. Notwithstanding the foregoing, records with
respect to submission and validation batches shall be retained by Supplier and be available
to Medicis
for the life of the Product. Supplier will notify Medicis prior to record destruction and
upon Medicis’s request, shall provide the records to Medicis at Medicis’s expense.

4.12 Regulatory Matters.

(a) Medicis shall fulfill all regulatory requirements with respect to the Product that are
imposed by Applicable Laws upon Medicis as the holder of the NDA. Supplier shall be
responsible for the registration of the Drug Establishment and maintaining the site
manufacturing license for the production of the Product. Supplier and Medicis shall provide
one another with information necessary to fulfill such regulatory obligations.

(b) Medicis shall have responsibility for the filing of all documents with the FDA or any
other regulatory authority or any other actions that may be required for the receipt of FDA
approval or any other regulatory authority approval for the Manufacture of all of the
Products hereunder. Supplier, at all times hereunder, shall assist Medicis to obtain FDA or
any other regulatory authority approval for the Manufacture of all Products hereunder as
quickly as reasonably possible. Medicis will provide to Supplier copies of applicable
sections of the NDA (i.e., those related to the Manufacture of Product at the Facility)
prior to applicable regulatory pre-approval inspections. Supplier shall review such
sections and promptly provide Medicis with revised sections, if applicable.

(c) Each Party may communicate with any governmental agency, including but not limited to
governmental agencies responsible for granting regulatory approval for the Products,
regarding such Products if in the opinion of that Party’s counsel, such communication is
necessary to comply with the terms of this Agreement or the requirements of any Applicable
Law, governmental order or regulation; provided, however, that unless in the reasonable
opinion of its counsel there is a legal prohibition against doing so, such Party shall
permit the other Party to accompany and take part in any communications with the agency, and
to receive copies of all such communications from the agency.

(d) Supplier shall notify Medicis immediately if Supplier receives: (i) any warning letters
from or on behalf of a governmental agency with respect to the Facility or Manufacture of
the Product including, without limitation, any Form FDA-483; or (ii) any notice of any
deficiencies noted or otherwise referenced

Medicis / Wellspring — Master Manufacturing Agreement

Page 8 of 24

 

by any governmental agency. Supplier shall
provide Medicis copies of any written communication from a governmental agency relating to a
Product within *** of its receipt.

(e) If either Party becomes engaged in or participates in any investigation, claim,
litigation or other proceeding with any Third Party, including but not limited to the FDA,
relating in any way to Product or Manufacture of Product, the other Party will cooperate in
all reasonable respects with the first Party in connection therewith, including, without
limitation, using its reasonable efforts to make available to the first Party or such Third
Party at the first Party’s expense, such of the other Party’s employees who may be helpful
with respect to such investigation, claim, litigation or other proceeding.

4.13 Annual Product Review.
After Medicis has provided written notice ***, Supplier shall provide Medicis with any data or other information that Medicis
or its designated third party determines is necessary to conduct an annual product review and in a
form and manner reasonably determined by Medicis. Such data shall include, without limitation,:
(a) Product information related to all batches produced, batch release (including results from its
suppliers), Yield evaluation, release testing data, deviations, rejections, change controls, and
validation activities; and (b) control charting or trend analysis of key parameters.

4.14 Inspection Rights.

	 	(a)	 	Medicis shall have the right to conduct *** Manufacturing Audit (as defined
below) *** according to the terms specified in this Section 4.14 hereof (such annual
Manufacturing Audit to be hereinafter referred to as an “Annual MA”).
	 
	 	(b)	 	In addition to the Annual MA, in the event that (i) Supplier is conducting
start-up activities, (ii) Supplier receives a FORM FDA 483 or a “Warning Letter” from
the FDA, Health Canada or any foreign equivalent outside Canada or the United States
relating to the manufacture, packaging or labeling of the Products by Supplier, (iii)
Medicis has rejected a batch of Product where it has been agreed or determined that
such Product failed to meet the Specifications or GMPs, (iv) Medicis or Supplier has
received a series of complaints (i.e., three or more complaints on at least two lots of
a Product) from third parties within any calendar year relating to the manufacture of
the Product, or (v) if there is a quality issue related to the Product, Medicis shall
have the right to conduct additional Manufacturing Audits according to the terms
specified in subsection (d) below (such additional Manufacturing Audit or Audits to be
hereinafter referred to as an “Incident MA”).
	 
	 	(c)	 	It is agreed that Medicis may arrange routine observational visits to
Supplier’s Facility of not longer than *** and in no greater frequency than *** in any
***.
	 
	 	(d)	 	For purposes of this Agreement, the term “Manufacturing Audit” shall mean an
audit of Supplier’s Facility by no more than *** Medicis employees and/or agents for
purposes of reviewing Supplier’s procedures and processes used in manufacturing and/or
packaging the Products. Any such agents shall be qualified to conduct manufacturing
audits, shall comply with all Supplier’s facility rules regarding safety and security
notified by Supplier to Medicis and its employees and/or agents and shall execute a
written agreement to maintain in confidence all information obtained during the course
of any such audit except for disclosure to Medicis subject to the terms hereof. Each
Manufacturing Audit shall be conducted during Supplier’s normal business hours and upon
at *** prior written notice to Supplier in the case of an Annual MA, or *** notice to
Supplier in the case of an Incident MA. In no event shall a Manufacturing Audit exceed
*** in duration, and in all cases Medicis shall ensure that its employees or agents
will conduct each Manufacturing Audit, to the extent reasonably possible, so as not to
interfere with the normal and ordinary operation of Supplier’s Facility. During a
Manufacturing Audit, upon Medicis’s request, Supplier shall make available for
Medicis’s review and inspection all equipment and facilities used in or in relation to
the manufacture and/or packaging of the Products, records and support documents (i.e.,
manufacturing and analytical) with respect to each batch of

Medicis / Wellspring — Master Manufacturing Agreement

 PAGE 9 OF 24

 

the Products and other raw materials and packaging components used in the
manufacture or packaging of the Products hereunder. At any such audit, Medicis
shall have the right to obtain copies of such batch records with respect to the
Product, provided that if this would involve Supplier incurring significant cost
then the parties will discuss appropriate cost sharing of those expenses.

	 	(e)	 	In the event Medicis provides Supplier with a written audit report, within
thirty (30) days of receipt of this audit report, Supplier shall provide Medicis in
writing a proposed action plan subject to Medicis’s prior written approval to address
the issues described by Medicis in the report.

4.15 Regulatory Inspections. Supplier shall inform Medicis in writing within *** of any
governmental or regulatory inquiry, communication, audit or inspection of the Facility, the
Services or Manufacturing processes relating to a Product. Medicis shall be given the opportunity
to provide assistance to Supplier in responding to any such inquiry, communication, inspection
relating to a Product. Medicis shall have the right to have a representative present at the
Facility during any governmental agency inspection relating to a Product. Supplier shall notify
Medicis in writing prior to entering into a consent decree or an order being entered against
Supplier involving Supplier failure, or alleged failure, to comply with cGMP.

4.16 Compliance with Section 6032 of Deficit Reduction Act of 2005. In accordance with Section
6032 of the Deficit Reduction Act of 2005, Pub. Law No. 109-171, Medicis has adopted a policy
entitled “Medicis Employee Education Policy Concerning the Prevention and Detection of Fraud,
Waste, and Abuse in Government Health Care Programs: Compliance Policy Pursuant to the Deficit
Reduction Act of 2005” (“Deficit Reduction Act Compliance Policy”), which establishes a written
protocol for educating all employees (including management) of Medicis, and any contractors or
agents who may on behalf of Medicis furnish or authorize the furnishing of Medicis health care
items or services, perform billing or coding functions, or become involved in monitoring any health
care provided by Medicis (“Applicable Agents”), about Medicis’s internal policies and procedures as
well as various federal and state statutes and administrative remedies related to detecting and
preventing fraud, waste, and abuse in government health care programs. It is a condition of this
Agreement that Supplier comply with the Deficit Reduction Act Compliance Policy, and that Supplier
provide the educational information required under the Deficit Reduction Act to all its Affiliates,
employees, or approved subcontractors who bear any responsibility in the performance of this
Agreement. A copy of Deficit Reduction Act Compliance Policy, as well as an addendum entitled
“Federal and State Statutes and Administrative Remedies Related to Preventing and Detecting Fraud,
Waste, and Abuse in Government Health Care Programs,” is available at www.Medicis.com/dra, and is
incorporated herein by reference. Upon request, copies of the Deficit Reduction Act Compliance
Policy will be provided to Supplier. Supplier represents and warrants that, in connection with
performing its obligations under this Agreement, it will comply with the Deficit Reduction Act
Compliance Policy.

ARTICLE 5

PRICING AND PAYMENT TERMS

5.1 General. Subject to the terms of this Article 5, Medicis shall pay to Supplier the
Price and Fees as set forth in the applicable Product Exhibit as Supplier’s total compensation for
Services. Unless otherwise indicated, all monetary amounts are expressed in the lawful currency of
the United States of America.

5.2

Price Adjustments. The Price shall be subject to periodic adjustment in
accordance with the following:

	 	(a)	 	***
	 
	 	(b)	 	***
	 
	 	(c)	 	***

Medicis / Wellspring — Master Manufacturing Agreement

Page
10 of 24

 

5.3 Delayed Shipment Discount. Supplier will notify Medicis immediately if it
believes it will not be able to ship the Product by the requested ship date in the purchase order.
Unless otherwise agreed to by both Parties, if Supplier ships the Product later than *** after the
requested ship date in the purchase order (“Grace Period”), and the failure to ship is not
attributable to Medicis or as a result of Force Majeure (defined in Section 13.6), then Supplier
will discount the Price by *** the Product does not ship after the Grace Period, up to ***. At
Medicis’s option, any amounts due under this Section shall be payable as a setoff against other
payments that Medicis may owe Supplier. If Supplier fails to ship Product by the requested ship
date in the purchase order for *** in a calendar year or *** over the term of the Product Exhibit,
Medicis shall have the right to terminate the Product Exhibit under Section 7.2 due to a material
breach, or declare that Product Exhibit non-exclusive (if agreement was exclusive) so that Medicis
may immediately begin to obtain any or all of its Product needs from another source. In the event
Medicis obtains Product from another source, then any Product obtained will reduce the Firm Order
accordingly. Supplier will reimburse Medicis for all ***.

5.4 Invoices. Except as otherwise provided in this Agreement, Supplier shall charge and
invoice Medicis for (a) those Products that are released and shipped to Medicis or a location
designated by Medicis; and (b) Services actually rendered by Supplier for Other Services in
accordance with a Product Exhibit and shall submit to Medicis with each invoice such documentation
as may be reasonably necessary to support the amounts set forth therein. Each invoice shall, to
the extent applicable, identify the Medicis purchase order number, Product numbers, names and
quantities, unit price, freight charges and the total amount to be remitted by Medicis. Supplier
shall invoice Medicis (referencing Medicis’s purchase order number) upon shipment of the applicable
Product, or completion of the applicable Services at the following address, unless otherwise
notified in writing by Medicis:

Medicis Global Services Corporation

Attn: Legal Department

8125 North Hayden Road

Scottsdale, AZ 85258-6276

5.5 Payment. Medicis shall pay all undisputed amounts invoiced in accordance with the
terms of this Agreement within *** following receipt of the invoice from Supplier prepared in
accordance with the terms of this Agreement.

ARTICLE 6

REPRESENTATIONS AND WARRANTIES

6.1 Authority. Each Party represents and warrants that it has the full right and authority
to enter into this Agreement, and that it is not aware of any impediment that would inhibit its
ability to perform its obligations hereunder.

6.2 Not Debarred. Supplier represents and warrants that it shall not use the services of
any Persons debarred or suspended under 21 U.S.C. § 335a(a) or (b) in any capacity associated with
or related to the Services. Furthermore, Supplier represents and warrants that it shall not hire
or retain as an officer or employee any Person who has been convicted of a felony under the laws of
the United States for conduct relating to the regulation of any drug product under the United
States Food, Drug, and Cosmetic Act. If at any time this representation and warranty is no longer
accurate, Supplier shall immediately notify Medicis of such fact

6.3 Capacity; Personnel. Supplier represents and warrants that: (a) Supplier has, and
shall use reasonable commercial efforts to maintain the resources and personnel necessary to
perform its obligations under this Agreement and each Product Exhibit in a timely manner; and (b)
without limiting Section 4.7, any individual used by Supplier to perform the Services are, and will
continue to be, qualified and have, and will continue to have, sufficient technical expertise to
perform Supplier’s obligations under this Agreement and each applicable Product Exhibit.

6.4 Title. Supplier represents and warrants that no Person (other than Medicis) shall, by
reason of Supplier acts or omissions, have any security interest, or lien on Medicis-Supplied
Material, Medicis-Owned Developments, Medicis Confidential Information, Medicis Technical Information or released finished Product.
Supplier further represents and warrants that the Medicis-Owned Developments, and Medicis’s use of the Medicis-Owned

Medicis / Wellspring — Master Manufacturing Agreement

Page
11 of 24

 

Developments shall not infringe upon, violate, nor be subject to any claim of
misappropriation of, any Third Party Intellectual Property or proprietary rights.

6.5 Shelf Life. Supplier represents and warrants that, unless otherwise mutually agreed
upon by the Parties, Product shipped to Medicis or other location of Medicis’s designation shall
have the shelf life specified in the Product Exhibit.

6.6 Compliance with Laws. Without limiting any terms or conditions of this Agreement,
Supplier represents and warrants that:

     (a) Supplier shall perform the Services in accordance with (i) the Applicable Laws; (ii)
current Good Laboratory Practices, cGMP or ICH Guidelines, (iii) the terms and conditions of the
Product Exhibit; (iv) generally prevailing industry standards; and (v) Medicis’s written
instructions consistent with the foregoing;

     (b) all Product, at the date shipped to Medicis or to a location of Medicis’s designation,
shall (i) fully conform to the applicable Specifications and Release Information; (ii) have been
Manufactured in compliance with the applicable regulatory requirements, cGMP, the Manufacturing
Requirements and all Applicable Laws; (iii) not be materially different from the potency specified
in the Certificate of Analysis, nor adulterated or misbranded within the meaning of any Applicable
Law; and (iv) not be Defective. Medicis may request Product to be shipped under “Restricted
Release” (Quarantine) under a planned deviation approved by responsible Quality Department
personnel from Medicis and Supplier, in which case the Specifications as defined in this Agreement
would refer to the specifications designated in writing by the Quality Department personnel from
Medicis and Supplier.

     (c) with respect to its overall operations or the Facility, (i) Supplier has and during the
Term shall comply with Applicable Laws; (ii) Supplier has not received any warning letters from or
on behalf of a governmental agency; (iii) any deficiencies noted or otherwise referenced in any
Form FDA-483 issued to Supplier have been corrected prior to the Effective Date; and (iv) is in
compliance with the applicable good manufacturing practices set forth in regulations promulgated by
the FDA.

6.7 Components. Supplier represents and warrants that no Product (and no Components
thereof) delivered pursuant to this Agreement shall be derived from or Manufactured using any human
components. Except as otherwise set forth in the Product Exhibit, Supplier further represents and
warrants that no Product (and no Components thereof) shall be derived from or Manufactured using
any animal components without the prior written consent of Medicis, which consent may be withheld
by Medicis by any reason.

6.8 Performance of Obligations. The Parties represents and warrant that it is not now a
party to any agreement which would prevent it from fulfilling its obligations under this Agreement
and during the Term of this Agreement it will not knowingly enter into any agreement with any other
party that would in any way prevent it from performing its obligations under this Agreement or any
Product Exhibit.

6.9 Intellectual Property. Supplier warrants that the sale, use or incorporation into
manufactured products of all Products and Services furnished by Supplier hereunder which are either
(a) not of Medicis’s design or composition or (b) not as specified in the Specifications, will not
infringe upon or dilute any U.S. or foreign patent, copyright, trademark, service mark, trade name
or other intellectual property right, and will not misappropriate any trade secret. In addition to
its other rights and remedies, Medicis shall have the right to cancel delivery of any Products or
Services to be provided hereunder to which any claim described in this Section relates and to
return to Supplier for full credit or refund any such Products or Services.

6.10 Additional Covenants of Medicis. Medicis shall:

	 	(a)	 	provide all information in Medicis’s possession or within its control that is
necessary for Supplier to Manufacture the Products in accordance with the
Specifications and all applicable laws, including GMPs; and

Medicis / Wellspring — Master Manufacturing Agreement

Page
12 of 24

 

	 	(b)	 	make its employees available on a timely basis to respond to questions
concerning such information.

6.11 Disclaimers.

	 	(a)	 	EXCEPT AS EXPRESSLY PROVIDED IN THIS ARTICLE 6, NEITHER PARTY MAKES ANY
REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW,
BY STATUTE OR OTHERWISE, AND BOTH PARTIES EXPRESSLY DISCLAIM ANY AND ALL IMPLIED OR
STATUTORY WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY,
WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF NON-INFRINGEMENT.
	 
	 	(b)	 	IN ADDITION, SUPPLIER MAKES NO WARRANTY REGARDING, AND SHALL HAVE NO LIABILITY
WITH RESPECT TO THE CONDUCT OF MEDICIS OR ANY THIRD PARTY OTHER THAN SUPPLIER’S
AFFILIATES, SUBCONTRACTORS AND REPRESENTATIVES.
	 
	 	(c)	 	SUPPLIER WILL NOT BE RESPONSIBLE FOR DELAYS ARISING FROM THE FAILURE OF MEDICIS
TO PROVIDE TO SUPPLIER THOSE MATERIALS, INFORMATION AND CO-OPERATION IN A TIMELY MANNER
THAT SUPPLIER ADVISES MEDICIS IN WRITING ARE REQUIRED IN ORDER FOR SUPPLIER TO PERFORM
ITS OBLIGATIONS ON A TIMELY BASIS INCLUDING THE DATES BY WHICH SUPPLIER REQUIRES SUCH
MATERIALS, INFORMATION AND CO-OPERATION. SUPPLIER WILL USE COMMERCIALLY REASONABLE
EFFORTS TO MEET THE AGREED UPON TIMELINES AND SPECIFICATIONS. SHOULD THE OCCASION
ARISE, SUPPLIER WILL ATTEMPT TO LIMIT THE EFFECT OF SUCH DELAYS AND WILL INFORM MEDICIS
OF THE DELAYS AND THEIR IMPACT TO THE TIMELINE.

6.12 Application/Survival. The warranties herein cover both Parties. No warranties shall
be deemed disclaimed or excluded unless agreed to in writing by an authorized representative of
both Parties. A Party’s approval of designs furnished by the other Party shall not relieve it of
its warranties under this Section. The warranties in this Section, and all other warranties
express or implied, shall survive delivery, final acceptance and payment pursuant to UCC 2-601 and
2-608.

ARTICLE 7

TERM, RENEWAL AND TERMINATION

7.1 Term. This Agreement shall be effective as of the Effective Date and shall expire at
*** (the “Initial Term”). At the end of the Initial Term, this Agreement shall continue
automatically for additional one (1) year periods (each a “Renewal Term,” together with the Initial
Term, the “Term”) under the same terms and conditions hereunder until terminated in accordance with
the terms of Section 7.2 of this Agreement.

7.2 Termination. This Agreement or a Product Exhibit may be terminated as follows:

	 	(a)	 	By mutual agreement of the Parties.
	 
	 	(b)	 	Upon failure of either Party to remedy its material breach of any of the
obligations or provisions of this Agreement within *** following receipt of written
notice of said breach, the aggrieved Party shall have the right to terminate this
Agreement immediately by written notice.
	 
	 	(c)	 	Either Party at its sole option may immediately terminate this Agreement upon
written notice, but without prior advance notice, to the other Party in the event that
(i) the other Party is declared insolvent or bankrupt by a court of competent
jurisdiction; (ii) a voluntary petition of bankruptcy

Medicis / Wellspring — Master Manufacturing Agreement

Page
13 of 24

 

is filed in any court of competent jurisdiction by such other party; (iii) a
receiver is appointed or applied for; or (iv) this Agreement is assigned by such
other Party for the benefit of creditors.

	 	(d)	 	By Medicis upon the occurrence of the following and Supplier fails to cure
within *** after receipt of written notice from Medicis identifying the breach. Such
termination shall be without liability to Medicis except for Product or Services
previously delivered and accepted.

	 	(i)	 	Supplier fails to make delivery of Products or Services on or before the
delivery date specified on the Product Exhibit, in accordance with the terms of
Section 5.3;
	 
	 	(ii)	 	Supplier materially breaches any material term, provisions, warranty,
representation obligation or condition of this Agreement;
	 
	 	(iii)	 	Supplier, due to its negligence or willful misconduct and excluding Force
Majeure events, fails to make progress as to endanger performance of the applicable
Product Exhibit in accordance with its terms; or
	 
	 	(iv)	 	Supplier ceases to conduct its operations in the normal course of business
(including inability to meet its obligations as they mature).

	 	(e)	 	By Supplier upon:

	 	(i)	 	a material breach by Medicis of Medicis’s obligations of confidentiality under
Article 8 of this Agreement if Medicis fails to cure such breach within *** after
receipt of written notice from the Supplier identifying the breach; or
	 
	 	(ii)	 	non-payment of an undisputed amount invoiced by Supplier to Medicis if Medicis
fails to cure such breach within *** after receipt of written notice from Supplier
identifying the non-payment and Supplier’s intent to terminate this Agreement
pursuant to this Section.

(f) Medicis may terminate this Agreement or any Product Exhibit as to any Products or
Services upon *** written notice in the event that any governmental agency takes any action,
or raises any objection, that prevents Medicis from importing, exporting, purchasing or
selling such Products. If the basis for the action results from the breach of this
Agreement by Supplier, Medicis shall have the right to terminate this Agreement with respect
to the affected Products and to Manufacture the Products itself or have the Products
Manufactured by a an alternate manufacturer.

(g) This Agreement or any Product Exhibit may be terminated by either Party for any reason
upon *** prior written notice.

(h) This Agreement may be terminated by either Party at the expiration of the Initial Term
or at the expiration of any Renewal Term upon not less than *** prior written notice to the
other Party.

7.3 Rights and Obligations Upon Termination.

(a) Each Product Exhibit shall terminate automatically and immediately upon termination of
the Agreement for any reason. Any termination of a Product Exhibit shall not be deemed to
be termination of this Agreement or any other Product Exhibit. At Medicis’s option, the
Initial Term or any Renewal Term will automatically be extended for any period commensurate
with the remaining term of any Product Exhibits which are then in effect. In such a case,
the termination of this Agreement will be the termination date of the last Product Exhibit
to terminate.

(b) Unless otherwise set forth in a Product Exhibit, Supplier shall retain samples of the
Products in accordance with Section 4.11. Supplier will contact Medicis to arrange for
proper disposal of all samples and all other chemical wastes generated by the Product
Exhibit at Medicis’s expense and direction.

Medicis / Wellspring — Master Manufacturing Agreement

Page 14 of 24

 

Notwithstanding the foregoing, all other Products and Medicis-Supplied Materials shall be
delivered or returned to Medicis, or, at Medicis’s direction, destroyed.

(c) Any termination or expiration of this Agreement shall not affect any outstanding
obligations or payments due hereunder prior to such termination or expiration, nor shall it
prejudice any other remedies that the Parties may have under this Agreement or otherwise.

(d) If this Agreement expires or is terminated in whole or in part for any reason other than
a default by Supplier, Medicis shall:

	 	(i)	 	***
	 
	 	(ii)	 	***
	 
	 	(iii)	 	***

In the event of the termination of this Agreement or any Product Exhibit for any reason ***,
Supplier agrees to continue to Manufacture Products for Medicis and its Affiliates and their
respective sublicensees pursuant to the terms and conditions of this Agreement until such
time as Medicis has transitioned successfully the Manufacture of the Products. Medicis
agrees to exercise commercially reasonable efforts to transition the Manufacture of the
Products, and Supplier shall provide the assistance reasonably necessary to effectuate such
transition including assisting Medicis in the transfer of relevant manufacturing technology
and information to another qualified manufacturing site.

(e) Supplier shall return to Medicis any unused Medicis-Supplied Material and all samples
and Specifications, records and data held or generated by Supplier in performing the
Services under this Agreement, provided however, that that one (1) copy of such
Specifications, records and data may be retained by Supplier for legal compliance purposes,
as means of determining any continuing obligation or confidentiality, but for no other
purpose.

7.4 Survival. The provisions of Articles 1, 6 and 8 through 13 and Sections 4.8, 4.9,
4.10, 4.11 and 7.3 shall survive the termination, expiration and non-renewal or completion of this
Agreement, except to the extent any provision of such Section is expressly limited to the term of
this Agreement or the Product Exhibit.

ARTICLE 8

CONFIDENTIALITY

8.1 Medicis Confidential Information. Supplier acknowledges and agrees: (a) that (i) any
documents or materials created pursuant to this Agreement, (ii) any plans, Specifications, designs,
data, results, information, works in progress and any other documents or material related to the
Product, and (iii) any information, works in progress, trade secrets, data or other secret,
sensitive or confidential material related to the business technology, products, systems, formulas,
practices, processes, customers or projects of Medicis that are disclosed to or become known by
Supplier during the Term of this Agreement and which are not generally known to the public
constitute the confidential information of Medicis including, without limitation, the Medicis
Patents, Medicis-Supplied Material and the Medicis Technical Information (collectively, the
“Medicis Confidential Information”); (b) to hold such Medicis Confidential Information in strict
confidence; (c) not to disclose such Medicis Confidential Information to any Third Party except to
Supplier’s Representatives on a need to know basis, provided such Representatives are subject to
confidentiality provisions substantially similar to those set forth herein protecting Medicis
Confidential Information; (d) to use such Medicis Confidential Information only as necessary to
perform the Services for Medicis under this Agreement; and (e) upon termination or expiration and
non-renewal of this Agreement, to destroy or return all tangible Medicis Confidential Information
(including tangible media containing Medicis Confidential Information) to Medicis, except that one
copy thereof may be maintained in the file of Supplier (subject to Supplier’s on-going compliance
with the obligations set forth herein) to document information developed. This

Medicis / Wellspring — Master Manufacturing Agreement

Page 15 of 24

 

provision shall supersede and replace any previous confidentiality or non-disclosure agreements
between the Parties with respect to the subject matter hereof and be deemed to cover all
information disclosed thereunder.

8.2 Supplier Confidential Information. Medicis acknowledges and agrees: (a) (i) that any
Supplier Technical Information that is not generally known to the public constitute the
confidential information of Supplier, and (ii) any information, works in progress, trade secrets,
data or other secret, sensitive or confidential material related to the business technology,
products, systems, formulas, practices, processes, customers or projects of Supplier including,
without limitation, the Supplier’s Patents, Material and Supplier Technical Information, and that
are (A) disclosed to or become known by Medicis during the Term of this Agreement, (B) not
generally known to the public, and (C) do not in any manner contain or use or in any way were
created, developed, devised or discovered by any Person using Medicis’s Confidential Information
(collectively the “Supplier Confidential Information”); (b) to hold such Supplier Confidential
Information in strict confidence; (c) not to disclose such Supplier Confidential Information to any
Third Party except to Medicis’s Representatives on a need to know basis, provided such
Representatives are subject to confidentiality provisions substantially similar to those set forth
herein protecting Supplier Confidential Information; (d) to use such Supplier Confidential
Information only as reasonably useful to further develop, manufacture, or commercialize any
Products or any formulation based on the Products; and (e) upon termination or expiration and
non-renewal of this Agreement, to destroy or return all tangible Supplier Confidential Information
(including tangible media containing Supplier’s Confidential Information) to Supplier, except that
one copy thereof may be maintained in the file of Medicis’s law department to document information
developed. This provision shall supersede and replace any previous confidentiality or
non-disclosure agreements between the Parties with respect to the subject matter hereof and be
deemed to cover all information disclosed thereunder.

8.3 Permitted Disclosures. Notwithstanding Sections 8.1 and 8.2, either Party may disclose
Medicis Confidential Information or Supplier Confidential Information in response to: (a) an order
from a court or governmental agency; (b) in response to a party in litigation, provided that an
appropriate protective order has been entered; or (c) if such disclosure is necessary to comply
with any other laws or regulations applicable to the disclosing party. Notwithstanding Section
8.2, Medicis may disclose Supplier Confidential Information to Third Parties either with (x)
Supplier’s written consent, not to be unreasonably withheld, or (y) pursuant to a written
confidentiality agreement with confidentiality obligations no less restrictive then the
confidentiality obligations of this Agreement, and as reasonably necessary (as determined by
Medicis) to further develop, enhance, improve, Manufacture, or commercialize any Products or any
formulations based on the Products.

8.4 Exceptions. Notwithstanding Sections 8.1 and 8.2, the foregoing restrictions on
disclosure of Confidential Information shall not apply to information that a Party can reasonably
demonstrate: (a) is or hereafter becomes generally available to the trade or public other than by
reason of any breach hereof; (b) was already known to the receiving Party at the time of
disclosure; (c) is disclosed to the receiving Party by a Third Party that has the right to disclose
such information without any obligations of confidentiality; or (d) is developed by or on behalf of
the receiving Party independently, without reliance on Confidential Information received hereunder.

ARTICLE 9

PROPRIETARY RIGHTS

9.1 License to Manufacture Product. During the Term, Medicis grants to Supplier a
non-exclusive, non-transferable license under the Medicis Patents and Medicis Confidential
Information to Manufacture the Products solely for Medicis, its Affiliates and their respective
Sublicensees and to perform the Other Services. The foregoing license granted to Supplier shall
terminate immediately with respect to a Product under a Product Exhibit upon termination or
expiration or non-renewal of the applicable Product Exhibit.

9.2 NDAs. Notwithstanding any assistance provided by Supplier in acquiring approval from
the FDA of any NDA, Medicis shall own all right, title and interest in and to each NDA.

9.3 Intellectual Property.

	 	(a)	 	Medicis shall retain ownership of all information, documents, and materials that Medicis
provides to Supplier in connection with the performance of this Agreement and all Product
Exhibits. Further,

Medicis / Wellspring — Master Manufacturing Agreement

Page 16 of 24

 

	 	 	 	Medicis shall have the right to obtain and use copies of all reports, documents and other
tangible materials generated by Supplier that are related to the Product as part of the
Services rendered under this Agreement.
	 
	 	(b)	 	Medicis shall own, and Supplier hereby assigns to Medicis, all right, title and interest
in and to any Intellectual Property developed by Supplier in the course of Supplier
performing the Services under this Agreement that arise from, are based on, or relate to
Supplier’s use of Confidential Information of Medicis or its Affiliates or the Product,
including without limitation, the composition or formulation of, apparatus, system,
processes or method of manufacture for or method of use of Product, any patents, trademarks,
service marks, trade names, slogans, logos, copyrights, trade dress, designs, moral rights,
know-how and goodwill associated with, related to or arises from Product and any
improvements, enhancements, modifications, changes or derivative works thereof
(collectively, the “Medicis Owned Developments”); provided, however, that Medicis Owned
Developments shall not include Supplier Owned Developments. As used herein, “Supplier Owned
Developments” means Intellectual Property that ***. With respect to Supplier Owned
Developments, Supplier hereby grants to Medicis a non-exclusive, irrevocable, royalty-free
license, with the right to sublicense, to use such Supplier Owned Developments in connection
with Product. Supplier shall have no rights of ownership or use in any Intellectual
Property owned by Medicis or any Medicis Owned Developments, including without limitation
the Product and related technology. Upon completion or termination of the Services under
the applicable Product Exhibit, Supplier shall disclose to Medicis all Medicis Owned
Developments developed as part of such Services.

9.4 Trademarks. Medicis hereby grants to Supplier a nonexclusive license to use the
trademarks MEDICIS PHARMACEUTICAL CORPORATION, MEDICIS, and any trademarks that are identified in a
Product Exhibit as a “Product Trademark,” for the sole purpose of labeling and packaging Product
that is Manufactured for Medicis in accordance with this Agreement. Any use by Supplier of a
Product Trademark is subject to Medicis’s prior written approval. Such license shall terminate
immediately upon termination or expiration of this Agreement or the Product Exhibit with respect to
a Product Trademark. Supplier may not sublicense its rights under this Section except with
Medicis’s prior written consent, which consent may be withheld by Medicis for any reason.

9.5 Settlement. If a Third Party asserts that the use of Supplier technology in the
Manufacture of the Product directly or indirectly infringes a patent or other right owned by such
Third Party, Supplier shall use commercially reasonable efforts to resolve the problem raised by
the asserted infringement. The matter shall be deemed resolved if Supplier obtains: (a) a license
permitting Medicis to use the Third Party patent rights or Third Party technology for the Product
with either no royalties or royalties payable by Medicis; or (b) an agreement from the Third Party
that: (i) no action will be taken against Medicis or Sublicensees, or (ii) that the patent or
other right is not infringed; or (c) a holding that the Third-Party patent is invalid, or the
Third-Party patent or other right is unenforceable or not infringed by a court of competent
jurisdiction from which no appeal has or can be taken.

ARTICLE 10

INDEMNITY

10.1 Indemnification by Medicis. Medicis shall indemnify, defend and hold Supplier, its
Representatives and their respective directors, officers, successors and permitted assigns
(“Supplier Indemnified Parties”) harmless from and against any and all Third Party liabilities,
losses, claims, demands, obligations, judgments, causes of action, assessments, fines, damages,
costs and expenses (including, without limitation, reasonable attorneys’ fees) (collectively,
“Claims”), in each case to the extent such Claims are based on, arise out of, or are caused by:
(a) a breach or inaccuracy of any representation or warranty made by Medicis in this Agreement or
any Product Exhibit; (b) any negligent, willful, or reckless action, misconduct, error, inaction or
omission of Medicis or its employees, agents or subcontractors; (c) any failure to perform any
covenant, obligation, agreement, undertaking, or responsibility of Medicis in this Agreement or a
Product Exhibit; (d) any allegation of infringement or misappropriation of patent, trade secret,
copyright or trademark rights or other intellectual property of any Third Party resulting from
Medicis’s instructions for labeling or packaging of the Products or Medicis’s design or
Specifications for the Products; or (e) the handling, possession, marketing, distribution,
promotion, sale, or use of Product following shipment of Product to Medicis by Supplier including,
but not limited to, any claim asserting strict liability, except with respect to any of the
foregoing under subsections (a), (b), (c), (d) or (e) to the extent such

Medicis / Wellspring — Master Manufacturing Agreement

Page 17 of 24

 

Claims are caused directly by, the negligence, gross negligence or willful misconduct of Supplier
or its Representatives or suppliers, any breach of any representation or warranty made by Supplier
in this Agreement, or Supplier failure to perform any covenant, agreement, undertaking or
responsibility of Supplier contained in this Agreement or a Product Exhibit. Notwithstanding the
foregoing, Medicis shall not be liable for any Claims to the extent caused by any of the Supplier
Indemnified Parties as determined in a final, non-appealable order of a court of competent
jurisdiction.

10.2 Indemnification by Supplier. Supplier shall indemnify, defend and hold Medicis, its
Representatives and their respective directors, officers, successors and permitted assigns
(“Medicis Indemnified Parties”) harmless from and against any and all Claims, in each case to the
extent such Claims are based on, arise out of, or are caused by: (a) a breach or inaccuracy of any
representation or warranty made by Supplier in this Agreement or any Product Exhibit; (b) a failure
by Supplier or its employees, agents, or subcontractors to perform the Services in accordance with
this Agreement or any Product Exhibit; (c) any negligent, willful or reckless action, misconduct,
error, inaction or omission of Supplier or its employees, agents or subcontractors; or (d) any
allegations of infringement or misappropriation of any patent or trade secret rights of a Third
Party arising out of Supplier’s or Supplier’s Representatives performance of the Services under
this Agreement not related to Medicis’s design or Specifications for the Products except with
respect to any of the foregoing under subsections (a), (b), (c) or (d), to the extent such Claims
are based on, arise out of, or are caused by, the negligence, gross negligence or willful
misconduct of Medicis or its Representatives or suppliers or any breach of any representation or
warranty made by Medicis in this Agreement, or Medicis’ failure to perform any covenant, agreement,
undertaking or responsibility of Medicis contained in this Agreement or a Product Exhibit.
Notwithstanding the foregoing, Supplier shall not be liable for any Claims to the extent caused by
any of the Medicis Indemnified Parties as determined in a final, non-appealable order of a court of
competent jurisdiction.

10.3 Procedures for Indemnification. The obligations and rights of the each of the parties
as an Indemnifying Party (as defined below) or as an Indemnified Party (as defined below) under
Sections 10.1 or 10.2, as the case may be, with respect to Claims that are subject to
indemnification as provided for in Sections 10.1 or 10.2 (a “Claim”) shall be governed by and be
contingent upon the following additional terms and conditions set forth in this Section 10.3. As
soon as a party becomes aware of a Claim (actual or threatened) for which it intends to seek
indemnification under Section 10.1 (in the case of Supplier) or Section 10.2 (in the case of
Medicis) (the party seeking indemnification being referred to as the “Indemnified Party” and the
party obligated for indemnification being referred to as the “Indemnifying Party”), the Indemnified
Party shall give the Indemnifying Party prompt written notice and shall permit the Indemnifying
Party to manage and have control over the defense of such Claim. The Indemnified Party agrees to
provide all reasonable information and assistance, at the Indemnified Party’s sole cost and
expense, to the Indemnifying Party in such defense. The Indemnifying Party is authorized to direct
all aspects of the defense for which it has an obligation of indemnification and defense hereunder,
including without limitation, selection of counsel, discovery, motions and settlement. The
Indemnifying Party may not, however, settle or dispose of any such matter in any manner which would
confess wrongdoing or otherwise adversely impact the rights or interest of the Indemnified Party
without the prior written consent of the Indemnified Party, which consent may not be unreasonably
delayed or withheld.

ARTICLE 11

LIMITATION OF LIABILITY

11.1 No Indirect Damages. Except as set forth in Section 11.3, neither Party to
this Agreement shall have liability to the other Party to this Agreement for special, incidental,
indirect, consequential, exemplary or punitive damages of any kind arising under this Agreement,
whether any such claim is based upon warranty, breach of contract, negligence, strict liability or
other tort, or any other legal theory, even if such Party has been advised of the possibility of
such damages.

11.2 Direct Damages. Except as set forth in Section 11.3, in no event shall either Party’s
liability hereunder exceed ***.

11.3 Exceptions. Sections 11.1 and 11.2 shall not apply to the following: (a) a Party’s
obligation to indemnify the other for Claims in Article 10; (b) the costs of a recall set forth in
Section 4.10; (c) either Party’s wrongful

Medicis / Wellspring — Master Manufacturing Agreement

Page 18 of 24

 

termination of this Agreement or abandonment of the performance of its obligations under this
Agreement or any Product Exhibit; (d) damages arising out of either Party’s gross negligence or
intentional misconduct or intentional inaction under this Agreement; or (e) damages due to a
Party’s breach of confidentiality.

ARTICLE 12

DISPUTE RESOLUTION

12.1 Senior Executives. In the event the Parties do not or are unable to reach a mutually
agreeable resolution within *** of receipt of written notice of any claim, dispute, or controversy,
the Parties’ respective project managers shall promptly elevate the dispute to representative
senior executives of each Party. These senior executives from each Party shall meet for
face-to-face negotiation within *** from the date of the original written notice. If the senior
executives do not reach a resolution within *** after such meeting, or if either Party does not
make a senior executive available for face-to-face negotiation as provided herein, if the Parties
choose not to submit to Voluntary Non-Binding Mediation in accordance with Section 12.2 then they
shall be free to pursue those remedies available to them at law or in equity subject to the terms
of this Agreement.

12.2 Voluntary, Non-Binding Mediation. If executive-level performance review is not
successful in resolving the dispute, the Parties may, but shall not be obligated to, mutually agree
in writing to submit the dispute to non-binding mediation. Mediation must occur within twenty (20)
Business Days after the Parties agree to submit the dispute to mediation. The Parties mutually
shall select an independent mediator experienced in the Services that are the subject of the
dispute, and each shall designate a representative(s) to meet with the mediator in good faith in an
effort to resolve the dispute. The specific format for the mediation shall be left to the
discretion of the mediator and the designated Party representatives and may include the preparation
of agreed-upon statements of fact or written statements of position furnished to the other Party.

12.3 Continued Performance; No Tolling of Cure Periods. Except where clearly prevented by
dispute, each Party agrees to continue performing its obligations under this Agreement and all
Product Exhibits while the dispute is being resolved, subject to continued performance by the other
Party of its obligations unless and until the dispute is resolved or until this Agreement or the
Product Exhibit is terminated in accordance with the terms of this Agreement or the Product
Exhibits. The time frame for a Party to cure any breach of the terms of this Agreement or any
Product Exhibit shall not be tolled by the pendency of any dispute resolution procedures.

12.4 ***

12.5 Equitable Relief. Notwithstanding the foregoing, either Party may apply to any court
having jurisdiction over the Parties and the subject matter of the dispute for a temporary
restraining order or preliminary injunction to enjoin the other Party from misappropriating or
infringing any Intellectual Property rights of the Party seeking such relief, or to enforce the
termination or confidentiality provisions of this Agreement.

ARTICLE 13

MISCELLANEOUS

13.1 Permits. Supplier shall obtain and maintain, at its own expense, the necessary
permits required for the Manufacture of the Products by Supplier to Medicis and its Representatives
under this Agreement, provided that Supplier shall not be responsible for obtaining or maintaining
any other permits or other regulatory approvals in respect of the Products or the Specifications,
which shall be the sole responsibility of Medicis.

Medicis / Wellspring — Master Manufacturing Agreement

Page 19 of 24

 

13.2 Insurance.

13.2.1 Property Damage. Medicis shall purchase and maintain insurance or may
self-insure to cover the Medicis-Supplied Material during shipment to Supplier. Supplier
shall purchase and maintain insurance to cover the Medicis-Supplied Material and other items
supplied by Medicis, work-in-process and finished goods while such items are at Supplier.

13.2.2 Liability. During the Term and for a period of *** thereafter, each party
shall obtain and maintain at its own cost and expense from a qualified insurance company,
comprehensive general liability insurance, including standard product liability insurance
designating the other party as an additional insured. Such policies will provide protection
against any and all claims, demands and causes of action arising out of any defects or
failure to perform, alleged or otherwise, of the Product or any material used in connection
therewith or any use thereof. The minimum amount of liability coverage required by this
Agreement shall be not less than *** for each occurrence for bodily injury liability,
personal injury liability, products liability, property damage liability, contractual
liability and completed operations liability and not less than *** annual aggregate limit.

13.2.3 Evidence of Coverage; Cancellation. Each Party will provide the other with a
certificate of insurance evidencing the applicable coverage and showing the name of the
issuing company, the policy number, the effective date, the expiration date and the limits
of liability. The insurance certificate shall further provide for a minimum of thirty (30)
calendar days written notice to the recipient of a cancellation of, or material change in,
the insurance. Each Party shall cause its insurance policy to name the other Party hereto
as an additional insured and a loss payee.

13.3 Notices. All notices and consents required or permitted to be given under this
Agreement shall be in writing and shall be deemed to have been duly given if and when (a) delivered
personally, (b) mailed by first class certified mail, return receipt requested, postage prepaid, on
the date certified by the U.S. Postal Service to have been received by the addressee, (c) by
facsimile, provided the sender personally calls the recipient and confirms receipt of such
facsimile, or (d) on the date certified by a nationally recognized overnight express courier
service to have been received by the recipient, as follows:

If to Supplier:

Attn: ***

WellSpring Pharmaceutical Canada Corp.

400 Iroquois Shore Road

Oakville, ON L6H 1M5, Canada

Fax: (905)337-7239

with a courtesy copy, which shall not constitute notice hereunder, sent to:

If to Medicis:

Medicis Global Services Corporation

Attn: Legal Department

8125 North Hayden Road

Scottsdale, AZ 85258-6276

Fax: (602) 808-3891

13.4 Publicity. Neither Party shall issue or release any media release or public
announcement (including any announcements made via any posting on the World Wide Web or Internet),
or other similar publicity announcing the existence of this Agreement or relating to any term or
condition of this Agreement in any country or the relationships created by this Agreement without
three (3) Business Days’ prior written notice, including by e-mail, to the other Party and the
prior agreement of the other Party on the relevant wording relating to the Agreement or term or
condition of the Agreement. Notwithstanding the foregoing, each Party shall have the right to
issue media

Medicis / Wellspring — Master Manufacturing Agreement

Page 20 of 24

 

releases, immediately and without prior consent of the other Party that disclose any information
required by the rules and regulations of the Securities and Exchange Commission, the New York Stock
Exchange (NYSE), National Association of Securities Dealers (NASD) or Applicable Law; provided that
the disclosing Party shall notify, including by e-mail, the other Party no later than
simultaneously with such issuance of such disclosure and shall use commercially reasonable efforts
to provide a copy of the relevant wording relating to the Agreement, or any term or condition
thereof to the other Party prior to the disclosure thereof. Supplier shall contact Medicis’s
Investor Relations Group for any such approval by Medicis.

13.5 Relationship Between Parties. The relationship of Supplier to Medicis shall be that
of an independent contractor, and no provision of this Agreement shall be construed to constitute
any Party as a partner or joint venturer of the other Party. Under no circumstances shall the
independent contractor or any employee of Supplier be considered an employee or agent of Medicis.
Except as may be more specifically set forth herein; (a) neither Party shall be liable in any
manner for the debts and liabilities of the other Party; (b) neither Party shall have any right by
virtue of this Agreement to bind the other Party in any manner whatsoever; and (c) each Party shall
be solely responsible for all costs and expenses incurred by it in performing its obligations under
this Agreement.

13.6 Force Majeure.

(a) If either Party is prevented from complying, either totally or in part with any of the
terms or provisions set forth herein (except for an obligation to make monetary payments),
by reason of force majeure, including, by way of example and not of limitation, fire, flood,
explosion, storm, strike, lockout or other labor dispute, riot, war, rebellion, acts of
terrorism, accidents, acts of God, acts of governmental agencies or instrumentalities,
failure of suppliers (including Medicis’s inability to obtain Medicis-Supplied Material from
a Third Party) or any other external or non-negligent internal cause or externally induced
casualty, which, in each instance, are beyond its reasonable control, whether similar to the
foregoing contingencies or not (“Force Majeure”), such Party shall provide written notice to
the other Party within *** following the occurrence of such event and shall identify the
requirements of this Agreement or such of its obligations as may be affected, and to the
extent so affected and beyond such Party’s reasonable control, such obligations shall be
suspended during the period of such disability. Delays caused by events for which a Party
could have but failed to take commercially reasonable steps to prevent or compensate for
(e.g. fire insurance) shall not be considered to be caused by Force Majeure events.

(b) If any raw materials, facility systems, or capacity are used for both Product and any
other products or purposes (such other products or purposes are collectively referred to as,
“Competing Products”), any allocation necessary as a result of a Force Majeure event shall
be made as between Medicis’s needs and the needs of any other Third Party to whom Supplier
has firm contractual obligations *** in the *** preceding the date of the event constituting
Force Majeure.

(c) The Party prevented from performing hereunder shall use reasonable efforts to remove
such disability, and shall continue performance whenever such causes are removed. The Party
so affected shall give to the other Party a good faith estimate of the continuing effect of
the Force Majeure condition and the duration of the affected Party’s nonperformance.

(d) If the period of any previous actual nonperformance of Supplier because of Supplier
Force Majeure conditions plus the anticipated future period of Supplier nonperformance
because of such conditions will exceed an aggregate of ***, Medicis may terminate this
Agreement by notice to Supplier. If the period of any previous actual nonperformance of
Medicis because of Medicis Force Majeure conditions plus the anticipated future period of
Medicis nonperformance because of such conditions will exceed an aggregate of ***, Supplier
may terminate this Agreement by notice to Medicis.

13.7 Binding, Nature, Assignments.

(a) This Agreement shall be binding upon and shall inure to the benefit of the Parties
hereto and their respective successors and assigns; provided, however, that neither Party
shall voluntarily, by operation of law or otherwise, assign or delegate any of its rights,
duties or obligations (including, without limitation, by engaging a subcontractor) under
this Agreement without the prior written consent of the other Party, which

Medicis / Wellspring — Master Manufacturing Agreement

Page 21 of 24

 

consent shall not: (i) be unreasonably withheld, delayed or conditioned nor (ii) require
the payment of any additional consideration. Notwithstanding the foregoing, Medicis may
assign this Agreement, without Supplier’s consent and without any additional consideration,
as part of an assignment or sale of all, or substantially all, of its assets to which this
Agreement relates provided Medicis provides Supplier with prior written notice of the
assignment and the entity to which the Agreement is assigned agrees to comply with all of
Medicis’s obligations under this Agreement.

(b) This Agreement also may be assigned by Medicis, in whole or in part, as part of an
assignment, sale or licensing of a Product(s) to which this Agreement relates to subject to
Supplier’s prior written consent, provided: (i) such consent shall not be unreasonably
withheld, delayed or conditioned and shall not be conditioned upon any additional payments
to Supplier; and (ii) the entity to which the Agreement is assigned agrees to comply with
all of Medicis’ obligations under this Agreement.

(c) Supplier acknowledges that such an assignment or sale may be structured as a license
with an option to purchase and that Medicis may be responsible for the Manufacture of the
applicable Products for a certain period of time, in which case the acquiring entity or
licensee shall place orders for Products through Medicis; (i) agrees that such a structure
shall not be a basis for withholding its consent; and (ii) agrees to fulfill such orders in
accordance with the terms and conditions of this Agreement.

13.8 Costs and Attorneys’ Fees. The prevailing Party in any suit or proceeding arising out
of or relating to this Agreement shall be entitled to recover all of its costs and expenses,
including reasonable attorneys’ fees.

13.9 No Waivers. No failure to exercise, delay in exercising, or single or partial
exercise of any right, power, or remedy by either Party shall constitute a waiver of, nor preclude
any other or further exercise of, the same or any other right, power, or remedy.

13.10 Severability. If any provision of this Agreement is held to be illegal, invalid, or
unenforceable under present or future laws, the legality, validity, and enforceability of the
remaining provisions shall not be affected thereby, and in lieu of such illegal, invalid, or
unenforceable provision there shall be added automatically as a part of the document a provision
that is legal, valid, and enforceable, and as similar in terms to such illegal, invalid, or
unenforceable provision as may be possible while giving effect to the benefits and burdens for
which the Parties have bargained hereunder.

13.11 Neither Party Considered Drafter. Despite the possibility that one Party may have
prepared the initial draft of this Agreement or played the greater role in the preparation of
subsequent drafts, the Parties agree that neither of them shall be deemed the drafter of this
Agreement and that, in construing this Agreement in case of any claim that any provision hereof may
be ambiguous, no such provision shall be construed in favor of one Party on the ground that such
provision was drafted by the other.

13.12 Cumulative Remedies. All remedies provided for in this Agreement shall be cumulative
and in addition to and not in lieu of any other remedies available to either Party at law, in
equity or otherwise.

13.13 Controlling Law, Jurisdiction and Venue. This Agreement is made under, and shall be
construed and enforced in accordance with, the laws of the State of New York, without regard to
that State’s conflict of law rules or principles. The Parties hereby submit to the jurisdiction
of, and waive any venue objections against, the United States District Court for the District of
New York and the state courts of New York, in any litigation or dispute arising out of this
Agreement.

13.14 Amendment. This Agreement may be modified or amended only by written agreement of
the Parties hereto signed by authorized representatives of the Parties.

13.15 Counterparts. This Agreement may be executed in any number of counterparts, each of
which when so executed and delivered shall be an original hereof, and it shall not be necessary, in
making proof of this Agreement, to produce or account for more than one counterpart hereof.

Medicis / Wellspring — Master Manufacturing Agreement

Page 22 of 24

 

13.16 Entire Understanding. This Agreement, the Quality Agreement, the Product Exhibit and
any other attachments, appendixes, exhibits, or schedules hereto and thereto, state the entire
understanding between the Parties with respect to the subject matter hereof, and supersedes all
earlier and contemporaneous oral and written communications and agreements or promises made with
respect to the same subject matter, and any other previous agreements, promises, or representations
of any kind with respect to the relationship between the Parties hereto.

IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by its duly
authorized representative as of the Effective Date.

	 	 	 	 	 	 	 	 	 
	MEDICIS GLOBAL SERVICES CORPORATION	 	WELLSPRING PHARMACEUTICAL
CANADA CORP.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 	 	 
	 

	 	 

	 	 	 	 

	 	 
	 

	 	Name: Mark A. Prygocki, Sr.
	 	 	 	Name:	 	 
	 

	 	Title: CFO and Treasurer
	 	 	 	Title:	 	 

Medicis / Wellspring — Master Manufacturing Agreement

Page 23 of 24

 

APPENDIX 1

DEVELOPMENT, TECHNICAL TRANSFER AND OTHER SERVICES

1. General. Supplier acknowledges and agrees that from time to time Medicis may
request, and Supplier shall provide, certain Other Services in accordance with the terms and
conditions of a mutually agreed Product Exhibit and this Agreement.

1.1 Performance Milestones. Supplier shall perform the Other Services in accordance with
the time frames and milestones set forth in the applicable Product Exhibit. Except as set forth in
Section 1.3 below, if Supplier fails to meet a deadline or milestone set forth in the Product
Exhibit for any reason (“Deadline”), then in addition to any other rights or remedies that may be
available to Medicis as provided in this Agreement and/or the applicable Product Exhibit or at law
or in equity, Medicis shall send Supplier written notice of such failure (“Default Notice”) (which
notice may be sent electronically). If Supplier does not perform with respect to such Deadline
within *** following the date of such Default Notice (“Default Period”), Medicis shall have the
right to the remedies set forth in Section 1.2.

1.2 Remedies for Defective Services.

	1.	 	Except as otherwise set forth in Section 1.3, in the event that Supplier’s performance of, or
failure to perform, the Other Services (excluding, but not limited to, Force Majeure, failure
to perform due to sanctions, warnings, orders or penalties imposed by any Governmental Bodies)
results in (a) the Services not being performed in accordance with the Product Exhibit,
including Supplier’s failure to meet any applicable Deadlines, (b) the Services and/or
deliverables having to be re-performed to obtain the desired result, and/or (c) the
deliverables containing errors or Defects (subsections (a), (b) and (c) are individually and
collectively referred to as the “Defective Services”), then in addition to any other rights or
remedies that may be available to Medicis as provided in this Agreement and/or the applicable
Product Exhibit or at law or in equity, Supplier shall, at no additional cost to Medicis and
at Medicis’s option (x) repeat the Defective Services until such time as Services have been
provided in accordance with the applicable Product Exhibit; or (y) refund to Medicis all
amounts paid by Medicis to Supplier in connection with the Defective Services and any affected
Services.
	 
	2.	 	In addition to each of the foregoing options, if Supplier fails to meet a Deadline in
accordance with Section 1.1 above, Medicis shall have the right, to the fullest extent
permitted by law, hold back any fees owed and not yet paid to Supplier pursuant to the Project
Exhibit (the “Hold Back Amount”). Medicis agrees to notify Supplier of its decision to
exercise its right of hold back, provided, that the failure to give such notice shall not
affect the validity of any such refusal to make payments. If, however, Supplier performs its
obligations within *** of the date of the expiration of the Default Period, Medicis shall
release to Supplier the entire Holdback Amount. If Supplier fails to perform its obligations
within *** following the date of the expiration of the Default Period, Medicis shall have the
right to retain the entire Hold Back Amount.

1.3 Exceptions to Remedies for Defective Services. Supplier shall not be liable for
Defective Services to the extent that: (a) Supplier is prevented from achieving a Deadline or from
performing its obligations under a Product Exhibit as a result of Medicis’s or a Third Party
Subcontractor’s failure to perform an obligation that is identified as a precondition to Supplier’s
ability to perform; or (b) Medicis’s failure to provide materials, information and co-operation
from Medicis required under the applicable Product Exhibit to perform the Other Services. In the
event a Defective Service is caused by Medicis or a Third Party Subcontractor, both Parties shall
work in good faith to determine an appropriate course of action and if needed, to modify the
applicable Product Exhibit Deadlines. As used herein, “Third Party Subcontractor” means any
subcontractor used by Supplier and authorized by Medicis to perform the Other Services.

1.4 Change in Scope of Services. No change will be made in the nature or scope of the
Other Services to be performed by Supplier or in the amounts to be paid by Medicis therefore
without the prior written approval of an authorized representative of each of Supplier and Medicis.

Appendix 1

Medicis / Wellspring — Master Manufacturing Agreement

Page 1 of 2

 

1.5 Progress Reports. Accompanying each monthly invoice submitted by Supplier to Medicis
will be a written report of Supplier’s progress and activities in carrying out the Other Services
during the month for which any such invoice is being submitted. All such reports shall be in such
detail and in such format as the Parties shall reasonably agree.

1.6 Project Managers. Each of Supplier and Medicis shall designate at least one (1)
individual to meet, in person or by telephone, on a regular basis as needed, but no less often than
once every month to discuss Supplier’s progress and activities as well as any problems that have
arisen in connection with performance by either Party in connection with the Other Services.

1.7 DISCLAIMER. WITH RESPECT TO FORMULATION DEVELOPMENT SERVICES ONLY, DUE TO THE NATURE
OF THE WORK INVOLVED, RESULTS OF THE DEVELOPMENT CANNOT BE GUARANTEED, HOWEVER, SUPPLIER WILL USE
GOOD FAITH AND COMMERCIALLY REASONABLE EFFORTS IN PERFORMING THE WORK OUTLINED IN THE APPLICABLE
PRODUCT EXHIBITS THAT INCLUDE DEVELOPMENT SERVICES TO ACHIEVE MEDICIS’S OBJECTIVE. MEDICIS
ACKNOWLEDGES THAT THE RESULTS OF SUCH DEVELOPMENT SERVICES ARE INHERENTLY UNCERTAIN AND THAT
ACCORDINGLY, THERE CAN BE NO ASSURANCE, REPRESENTATION OR WARRANTY BY SUPPLIER THAT THE SERVICES
PROVIDED THEREUNDER CAN OR WILL RESULT IN A FORMULATION THAT WILL RECEIVE THE REQUIRED APPROVAL(S)
FROM THE FDA, OR OTHER REGULATORY AGENCY OR AUTHORITY.

Appendix 1

Medicis / Wellspring — Master Manufacturing Agreement

Page 2 of 2

 

SCHEDULE 1.1

DEFINITIONS

As used in this Agreement, the following capitalized terms shall have the meanings set forth below:

“Affiliate” means any Person which any Party directly or indirectly through one or more
intermediaries controls or which is controlled by or under common control with such Party. For the
purpose of this definition, “control” means the possession, direct or indirect, of the power to
direct or cause the direction of the management and policies of an individual, corporation or other
legal entity, whether through the ownership of voting securities, by contract, or otherwise.

“Applicable Laws” mean all applicable federal, state, provincial and local laws, statutes,
ordinances, rules, and regulations of any kind whatsoever, and any applicable orders, injunctions,
or decrees of any court, administrative agency, or similar authority, whether federal, state,
provincial, or local, including the laws, rules and regulations imposed by the United States Food
and Drug Administration.

“Business Day” means any day other than a Saturday, a Sunday or a day on which banks in Arizona or
Ontario, Canada are authorized or obligated by Applicable Law or executive order to remain closed.
Unless otherwise specified, the “days” shall mean “Business Days.”

“Calendar Quarter” or “Quarterly” means the three-month period ending on March 31, June 30,
September 30 or December 31.

“cGMPs” mean current good manufacturing practices as described in Parts 210 and 211 of Title 21 of
the United States’ Code of Federal Regulations and the latest FDA guidance documents pertaining to
manufacturing and quality control practice, all as updated, amended and revised from time to time.

“Components” mean, collectively, all raw materials necessary for Services or supply of Product
described in the applicable Product Exhibit (excluding Medicis-Supplied Material), including but
not limited to excipients, packaging components and printed material components.

“Defect” means an impurity, contamination or non-conformity in the Product caused by (i) a
non-conformance to the Specifications and/or the Manufacturing Requirements; and/or (ii) the
negligence or willful misconduct of Supplier, or its Representatives. Product that is subject to a
Defect may be referred to herein as “Defective.”

“Deficiency Notice” means a written notice from Medicis claiming (a) a Defect(s) with respect to
the Product and/or (b) shortages in the amount of delivered Product.

“Facility” means Supplier’s manufacturing facility located at 400 Iroquois Shore Road, Oakville,
Ontario L6H 1M5 Canada.

“Fees” mean the fees to be charged by Supplier for Other Services as set forth in the applicable
Product Exhibit.

“FDA” means the United States Food and Drug Administration and any successor agency or entity that
may be established thereafter.

“Intellectual Property” means all rights under patent, trademark, copyright and trade secret laws,
and any other intellectual property or proprietary rights recognized in any country or jurisdiction
worldwide now or in the future.

“Inventory” means all inventories of Components and work-in-process produced or held by Supplier in
connection with the Manufacture of the Products in accordance with the Specifications.

“Labeling” means the label affixed to the applicable container, the package insert and the
applicable container carton or any Product specific printed information packaged with such Product.

Medicis / Wellspring — Master Manufacturing Agreement

Schedule 1.1

Page 1 of 3

 

“Manufacture” means the manufacturing, supplying, testing, packaging, labeling, storing and
preparing for shipment (FCA Supplier’s Facility) to Medicis or to a location designated by Medicis.

“Manufacturing Requirements” mean Supplier’s responsibilities and obligations as set forth in
Articles 3 and 4 as well as the Product Exhibit.

“Medicis Patents” mean those patents (including all reissues, extensions, substitutions,
confirmations, re-registrations, re-examinations, re-validations, patents of addition,
Supplementary Protection Certificates or the equivalents thereof) and patent applications
(including, without limitation, all continuations, continuations-in-part and divisional): (i) that
are owned by, licensed to, or otherwise controlled by, Medicis and claim an invention necessary for
the Manufacture of Product by Supplier under the terms of this Agreement; or (ii) under which
Medicis has a right to have Product or Medicis-Supplied Material made and that, in each case, claim
an invention necessary for the Manufacture of Product by Supplier under the terms of this
Agreement.

“Medicis-Supplied Material” means the material or formulations to be supplied by Medicis, as
specified in the applicable Product Exhibit, for the Manufacture of Product by Supplier.

“Medicis-Supplied Material Specifications” mean the specifications for Medicis-Supplied Material,
which specifications are set forth in the applicable Product Exhibit.

“Medicis Technical Information” means any information provided by, or on behalf of, Medicis to
Supplier relating to the Product and/or the Services including, without limitation:

	 	(i)	 	a detailed description of the Product and any Medicis-Supplied Material,
including their respective physical and chemical characteristics and stability;
	 
	 	(ii)	 	the Labeling;
	 
	 	(iii)	 	shipping and storage requirements; and
	 
	 	(iv)	 	all environmental, health and safety information relating to the Product
including material safety data sheets, incident reports, risk analyses, health
concerns, preventative measures and procedures for waste disposal, all as updated,
amended and revised from time to time by Medicis.

“Minimum Yield” means the minimum percent Yield identified in the applicable Product Exhibit.

“NDA” means the New Drug Application that may be identified in the applicable Product Exhibit,
including any subsequent submissions, supplements, or amendments thereto.

“Other Services” mean development services, technical transfer services and any other services to
be provided by Supplier to Medicis under a Product Exhibit and this Agreement but specifically
excluding the commercial Manufacture of Product.

“Person” means a natural person, a corporation, a partnership, a trust, a joint venture, a limited
liability company, any Governmental Body, or any other entity or organization.

“Price” means the price that Supplier will charge to Medicis for the Manufacture of the Product as
set forth in the applicable Product Agreement.

“Product” means the various forms and presentations of the products described in the applicable
Specifications. Products may include commercial and non-commercial product including, but not
limited to, product in development and product for pre-clinical, clinical, research and/or
development purposes.

Medicis / Wellspring — Master Manufacturing Agreement

Schedule 1.1

Page 2 of 3

 

“Product Exhibit” means one or more exhibits that are signed by authorized representatives of the
Parties, reference this Agreement, describe the Product and/or Services to be supplied or otherwise
provided by Supplier under this Agreement and contain the information described in Section 2.3 of
this Agreement.

“Quality Agreement” means an agreement between the Parties that describes the quality and
regulatory responsibilities relating to the Manufacture and release for sale of Product to Medicis
or its designees, which agreement will be attached hereto and incorporated herein by reference as
Exhibit B.

“Reimbursement Value” means the actual replacement cost of the Medicis-Supplied Material to Medicis
at the time of replacement, as evidenced by supporting documentation to be provided by Medicis upon
request.

“Representatives” mean with respect to a Party: (i) its Affiliates, contractors and subcontractors,
and (ii) the agents, employees, consultants, lenders, investors, and advisors of such Party and its
Affiliates, contractors and subcontractors.

“Services” mean all of the services provided or to be provided by Supplier under this Agreement
including, without limitation, the Manufacture of Product and Other Services.

“Specifications” mean the specifications in effect at the time of execution for Manufacturing and
testing such Product as referred to in the applicable Product Exhibit, copies of which are
maintained by both parties’ Quality Departments and may be amended from time to time by Medicis in
accordance with the terms of this Agreement.

“Sublicensee” means a Third Party who has licensed or sublicensed rights to the Product from
Medicis.

“Supplier Technical Information” means all proprietary know-how, trade secrets, unpatented
inventions, technical data or information, manufacturing systems, practices, processes and
knowledge concerning the Manufacture of the Product, which are now owned, licensed, developed or
controlled, in whole or in part, by or on behalf of Supplier or any of its Affiliates and which are
necessary or useful for Manufacturing the Product. Supplier Technical Information does not include
Medicis Confidential Information.

“Third Party” means a Person other than Medicis, Supplier or an Affiliate of Medicis or Supplier.

“United States” means the fifty (50) states and the District of Columbia constituting the United
States of America and any territory owned or controlled by the United States of America including,
without limitation, Puerto Rico.

“Yield” means the actual amount of such Product shipped to Medicis or to a location designated by
Medicis, expressed as a percentage of the theoretical amount of such Product that could have been
produced from the amount of Medicis-Supplied Material used to Manufacture such Product, calculated
on a batch-by-batch basis.

Medicis / Wellspring — Master Manufacturing Agreement

Schedule 1.1

Page
3 of 3

 

EXHIBIT A

PRODUCT EXHIBIT # [__]

     This PRODUCT EXHIBIT #[___] (the “Product Exhibit”) effective as of                      ___, 2008 (the
“Effective Date”) is by and between Medicis Global Services Corporation, a Delaware corporation,
having offices at 8125 North Hayden Road, Scottsdale, AZ, 85258 (hereinafter “Medicis”), and
WellSpring Pharmaceutical Canada Corp., having offices at 400 Iroquois Shore Road, Oakville, ON L6H
1M5, Canada (hereinafter “Supplier”). Medicis and Supplier are sometimes referred to herein
individually as a “Party” and collectively as the “Parties.”

Medicis and Supplier agree that this Product Exhibit is entered into pursuant to the Master
Manufacturing Agreement between Medicis and Supplier dated                      (the “Agreement”). The Product
and Services described herein shall be governed by the terms, conditions and obligations set forth
in the Agreement and this Product Exhibit, and the terms of the Agreement are hereby incorporated
into this Product Exhibit by reference. Notwithstanding the incorporation by reference of the
Agreement into this Product Exhibit, in the event of conflict between the terms, conditions and
obligations of this Product Exhibit and the Agreement, the terms, conditions and obligations of
this Agreement shall govern. Capitalized terms not otherwise defined herein shall have the meaning
given them in the Agreement.

	1.	 	Medicis-Supplied Material. The Medicis-Supplied Material is described on Attachment
1 to this Product Exhibit.
	 
	2.	 	Product Specifications. The Product Specifications are described on Attachment 2 to
this Product Exhibit.
	 
	3.	 	Medicis Obligations. Medicis shall provide the following to Supplier in accordance with
the following time periods:

	 	i.	 	At least                      (___) weeks prior to the Commencement Date, any
Labeling to be printed by Supplier on the Finished Product, all of which shall be
in conformity with the regulations of the United States Food and Drug
Administration and any other applicable federal, state or local Governmental Body
	 
	 	ii.	 	At least                      (___) weeks prior to the Commencement Date, any
Medicis-Supplied Materials;
	 
	 	iii.	 	At least                      (___) weeks prior to the Commencement Date, the
lot and expiry information of the Products;
	 
	 	iv.	 	At least                      (___) weeks prior the Commencement Date, the
Medicis-Supplied Material Specifications;
	 
	 	v.	 	At least                      (___) weeks prior the Commencement Date, the
Medicis Technical Information; and
	 
	 	vi.	 	At least                      (___) weeks prior the Commencement Date, the
Specifications.

	4.	 	Start-Up Activities. “Start-Up Activities” means those activities required by the
Medicis or Supplier that are necessary to commence the Manufacture of Products as set forth on
Attachment 3 to this Product Exhibit.
	 
	5.	 	Minimum Batch Size. The minimum batch size is                      (                    ).
	 
	6.	 	Minimum Yield. “Minimum Yield” shall mean the yield set forth in writing by the
Supplier Relationship

Exhibit A — Product Exhibit #[_]

Medicis/Wellspring Master manufacturing Agreement

Page
1 of 2

 

Team prior to the Commencement Date. The Supplier Relationship Team may change the Minimum
Yield from time to time. Any setting of the Minimum Yield must be signed by an authorized
representative of each Party and are hereby incorporated into this Product Exhibit by
reference.

	7.	 	NDA. “NDA” shall mean the New Drug Application Number                      and any subsequent
submissions, supplements or amendments thereto.
	 
	8.	 	Product. “Product” shall mean various presentations of the finished product
containing Medicis-Supplied Material and as described in the Specifications.
	 
	9.	 	Product Specifications. The Specifications for Manufacturing and testing the Product
are set forth on Attachment 2 to this Product Exhibit.
	 
	10.	 	Shelf Life and Storage Requirements. Product shipped to Medicis or other location of
Medicis’s designation shall have a shelf life of at least                      (                    ) months from the date
of shipment. The storage requirements for the Product are set forth on Attachment 4 to this
Product Exhibit.
	 
	11.	 	Price Schedule.
	 
	12.	 	Minimum Order Quantities.

	 	 	 	 	 	 	 	 	 
	MEDICIS GLOBAL SERVICES CORPORATION	 	WELLSPRING PHARMACEUTICAL
CANADA CORP.
	 
	 	 	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 	 	 
	 

	 	 

	 	 	 	 

	 	 
	 

	 	Name:
	 	 	 	Name:	 	 
	 

	 	Title:
	 	 	 	Title:	 	 

Exhibit A — Product Exhibit #[_]

Medicis/Wellspring Master manufacturing Agreement

Page 2 of 2

 

ATTACHMENT 1

MEDICIS-SUPPLIED MATERIAL SPECIFICATIONS

[TO BE PROVIDED]

Attachment
1 to Product Exhibit #[_]

Medicis / Wellspring Master manufacturing Agreement

Page 1 of 1

 

ATTACHMENT 2

PRODUCT SPECIFICATIONS

[TO BE PROVIDED]

Attachment 2 to Product Exhibit #[___]

Medicis / Wellspring Master Manufacturing Agreement

Page 1 of 1

 

ATTACHMENT 3

START-UP ACTIVITIES

[TO BE PROVIDED]

Attachment 3 to Product Exhibit #[___]

Medicis / Wellspring Master Manufacturing Agreement

Page 1 of 1

 

ATTACHMENT 4

SHELF LIFE AND STORAGE REQUIREMENTS

[TO BE PROVIDED]

Attachment 4 to Product Exhibit #[___]

Medicis / Wellspring Master Manufacturing Agreement

Page 1 of 1

 

EXHIBIT B:

QUALITY AGREEMENT (QA)

[TO BE PROVIDED BY MEDICIS]

Exhibit B

Medicis / Wellspring Master Manufacturing Agreement

Page 1 of 1

 

EXHIBIT B: QUALITY AGREEMENT (QA)

Overview

This Quality Assurance Agreement (“Quality Agreement”) is effective as of March 20, 2008
(“Effective Date”) between WellSpring Pharmaceutical Canada Corp (hereinafter referred to as
“WPCC”) located at 400 Iroquois Shore Road, Oakville, Ontario, L6H 1M5 and Medicis Global Services
Corporation (hereinafter referred to as “Medicis”), located at 8125 North Hayden Road, Scottsdale,
Arizona, USA, 85258. Any capitalized terms not otherwise defined in this Quality Agreement shall
have the meaning ascribed to it in the Master Manufacturing Agreement between Medicis and WPCC,
dated March 11, 2008 (“MMA”). In the event of a conflict between the terms of the Quality Agreement
and the MMA, the MMA shall control.

This Quality Assurance Agreement sets out certain responsibilities of the parties relating to the
Manufacture of the Products listed in Appendix I to this Quality Agreement, which responsibilities
are in addition to those set forth in the MMA. This Quality Agreement has been drawn up according
to Title 21 of the US Code of Federal Regulations parts 210 & 211, Current Good Manufacturing
Practices, as amended from time to time and will apply respectively to Product Manufactured for
U.S. distribution.

Term of Quality Agreement

     The term of this Quality Agreement shall be coterminous with the term of the MMA; provided,
however, in the event that the MMA is terminated for any reason, the Quality Agreement shall remain
in effect and apply to those Products remaining in the field and stability commitments.

Revisions to Agreement

No amendment to the terms of this Quality Agreement shall be binding on the parties hereto unless
made in writing and signed by an authorized representative of each of the parties.

Communication

     The parties have identified and listed in Appendix II a list of personnel responsible for the
administration of this Quality Agreement. Personnel may be added or deleted to Appendix II upon
written notice to the other party.

Responsibilities

     The parties agree that WPCC and Medicis will be responsible for all operations marked with an
“X” in their respective column and will provide cooperation if marked with an “o”. An “X” in both
columns indicates each party is responsible for complying with or performing the applicable
activity.

1

 

AREA OF RESPONSIBILITY — GENERAL

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	WPCC	 	MEDICIS
	 	1.	 	 	Provide Specifications to Manufacture Product in compliance with regulations,
FDA guidelines, industry standards and product processing documents.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	2.	 	 	Manufacture Product in strict adherence to the approved Specifications,
Applicable Laws, applicable site SOPs, cGMPs and NDA/ANDA submissions.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	3.	 	 	As per the Generic Drug Enforcement Act of 1992, is not debarred nor shall
employ or use the services of any individual who is debarred.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	4.	 	 	Not to subcontract any work, including raw material, bulk and/or finished
Product laboratory testing, to any Third Party, other than those listed in Appendix
III, without prior written approval from *** in accordance with Section 13.7(a) of
the MMA.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	5.	 	 	Provide tabulated information and a cGMP annual product review report in
compliance with 21 CFR 211.180(e).

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	6.	 	 	Provide to *** required information for annual reports and other documents to
support Medicis regulatory filings and commitments upon request including
qualification documentation.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	7.	 	 	Notify *** within one (1) Business Day of receipt of an governmental or
regulatory inquiry, communication, audit or inspection of the Services, Facilities,
or Manufacturing processes relating to a Product.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	8.	 	 	Responsible for the registration of the Drug Establishment and maintaining the
site manufacturing license for the production of the Product.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	9.	 	 	Review and approve responses to regulatory authorities directly related to the
Product prior to submission to the regulatory authority and *** shall cooperate
with *** in accordance with the MMA, including without limitation Section 4.12].

	 	***
	 	***

AREA OF RESPONSIBILITY – QUALITY SYSTEMS

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	WPCC	 	MEDICIS
	 	10.	 	 	Notify *** as soon as possible and not longer than one (1) business day of
areas of concern identified during the review of any Medicis product documents,
requests for Medicis product samples or notice of inspections for a Medicis
product.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	11.	 	 	Liaise with regulatory authorities for approval and ongoing maintenance of
submissions as it pertains to the product .

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	12.	 	 	Perform services, quality assurance and quality control testing in accordance
with applicable nda, regulatory approvals, the batch records, all applicable laws,
specifications, and cgmps.

	 	***
	 	***

QUALITY SYSTEMS – CHANGE CONTROL

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	WPCC	 	MEDICIS
	 	13.	 	 	Notification of all changes to product including, process and controls (e.g.
Changes in raw materials/packaging materials specifications, test methods,
manufacturing processes, product specifications, master batch records etc.) In
accordance to the provisions of the mma including without limitation section 4.3.1.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	14.	 	 	Approve any changes impacting regulatory submissions, specifications and/or
impacting the identity, strength, quality, purity, potency, safety, efficacy and
availability of the product.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	15.	 	 	Provide regulatory input on timing of changes for appropriate products.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	16.	 	 	Update relevant documents affected by changes described in section 12 of this
quality agreement.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	17.	 	 	Approve relevant documents provided under section 15 of this quality agreement.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	18.	 	 	Provide copies of approved, implemented documents within 15 days of approval.

	 	***
	 	***

2

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	QUALITY SYSTEMS – DOCUMENTATION	 	WPCC	 	MEDICIS
	 	19.	 	 	Create master batch record (includes formulation, filling and packaging) based
on Medicis technical information.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	20.	 	 	Approve master batch record.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	21.	 	 	Generate, issue and execute accurate copies of the master batch record.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	22.	 	 	Create raw material, product, packaging and testing specifications based on
Medicis technical information.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	23.	 	 	Approve raw material, product, packaging and testing specifications.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	24.	 	 	Maintain records and evidence of the testing of components for *** after the
components are last used in the manufacture of the product

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	25.	 	 	Retain originals of non-validation and non-developmental batch documentation
and representative samples from each product lot as required by the cfr or in any
event for at least *** past the expiry of the product.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	26.	 	 	Maintain executed batch records for validation and developmental batches for
the life of the product and product line. Provide copies to ***.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	27.	 	 	Provide copies of entire batch records to *** for their files, submissions or
for investigative purposes as requested.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	28.	 	 	Submit field alert reports.

	 	***
	 	***

	 	 	 	 	 	 	 	 	 
	 	 	 	 	QUALITY SYSTEMS – DEVIATIONS AND INVESTIGATIONS	 	WPCC	 	MEDICIS
	 	29.	 	 	Notify *** of any major deviation impacting the quality, strength, purity,
safety and compliance of a product lot or methods used for the manufacture, of a
product within *** of its occurrence.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	30.	 	 	Conduct investigation of major and minor deviations.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	31.	 	 	Create deviation/investigation report for major and minor deviations.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	32.	 	 	Review and approve the final deviation/investigation report for major
deviations.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	33.	 	 	Provide copies of final major and minor deviation/investigation report with
batch documentation.

	 	***
	 	***

	 	 	 	 	 	 	 	 	 
	 	 	 	 	QUALITY SYSTEMS - COMMERCIAL PRODUCT RELEASE & RECALL	 	WPCC	 	MEDICIS
	 	34.	 	 	No less than *** prior to the requested shipment date, provide *** a
certificate of conformance, certificate of analysis, copies of labeling, applicable
sections of the batch records or upon *** request the complete batch record, copy
of investigations and deviations for each bulk and finished product in accordance
with the mma including without limitation section 3.3(b).

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	35.	 	 	All deviations and oos investigations must be closed prior to batch release and
a copy of the closed investigation included in the batch record. Long-term capa
items may remain open with agreement from Medicis.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	36.	 	 	Release of bulk product for filling and packaging.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	37.	 	 	Release of finished product for commercial distribution.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	38.	 	 	Initiate product recall.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	39.	 	 	Participate in product recall investigations at *** request.

	 	***
	 	***

	 	 	 	 	 	 	 	 	 
	 	 	 	 	QUALITY SYSTEMS - LAB TESTING	 	WPCC	 	MEDICIS
	 	40.	 	 	Supply/develop and validate analytical test methods for finished product and
raw materials if non-compendial.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	41.	 	 	Verify compendial methods as per internal sops.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	42.	 	 	Coordinate all bulk and finished product testing activities, including
stability.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	43.	 	 	Develop test method transfer protocols.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	44.	 	 	Test method transfer protocol execution – raw materials, bulk & finished
product analytical methodology.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	45.	 	 	Review & approve test method transfer protocols, data and final report for raw
materials, bulk and finished product.

	 	***
	 	***

3

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	QUALITY SYSTEMS – OUT OF SPECIFICATIONS (“OOS”) INVESTIGATIONS	 	WPCC	 	MEDICIS
	 	46.	 	 	Out of specification investigation –provide report to ***.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	47.	 	 	Notify *** in writing within *** of a batch failure, deviation, or within ***
of a confirmed oos test result for commercial release testing. It is understood by
both parties that *** may complete an internal laboratory investigation without
requiring a *** quality signature, but shall place a copy of the completed report
in the batch record as part of *** final batch record review and disposition prior
to release.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	48.	 	 	Review and approve any confirmed oos or non-conformance reports (ncr).

	 	***
	 	***

	 	 	 	 	 	 	 	 	 
	 	 	 	 	QUALITY SYSTEMS - STABILITY PROGRAM	 	WPCC	 	MEDICIS
	 	49.	 	 	Responsibility for stability programs complying with applicable regulatory
guidance & product filings, including the suitability of the expiry period to the
formulation and packaging system.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	50.	 	 	Assign expiration dating.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	51.	 	 	Designate which lots are to be placed on stability.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	52.	 	 	Provide validated stability indicating assay.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	53.	 	 	Generate stability protocol.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	54.	 	 	Approve stability protocol.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	55.	 	 	Execute stability protocol testing.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	56.	 	 	Notify *** of any stability failure for product within *** of discovery.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	57.	 	 	Provide stability data reports within *** of completion of testing.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	58.	 	 	All missed stability test stations will be properly investigated and
documented. *** will be notified of missed test stations. (provide copy of
deviation investigation)

	 	***
	 	***

	 	 	 	 	 	 	 	 	 
	 	 	 	 	QUALITY SYSTEMS - RESERVE SAMPLES	 	WPCC	 	MEDICIS
	 	59.	 	 	Retain reserve samples of finished product for *** beyond product expiry.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	60.	 	 	Perform annual reserve sample inspection as per 21cfr 211.170. Provide reports
at time of annual product review per product.

	 	 ***
	 	***

	 	 	 	 	 	 	 	 	 
	 	 	 	 	QUALITY SYSTEM – CUSTOMER COMPLAINTS INVESTIGATION	 	WPCC	 	MEDICIS
	 	61.	 	 	Complete an investigation of a complaint within *** of receipt of a request by
***.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	62.	 	 	Investigate complaints related to the manufacture of the products.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	63.	 	 	Investigate complaints related to the effectiveness of product.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	64.	 	 	Investigate complaints related to the adverse effects of the product.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	65.	 	 	Reply to complainant.

	 	***
	 	***

	 	 	 	 	 	 	 	 	 
	 	 	 	 	QUALITY SYSTEMS – AUDITS	 	WPCC	 	MEDICIS
	 	66.	 	 	Permit audits of all relevant premises, processes, procedures and documentation
by *** or its representatives and notify *** of any inspection by regulatory
authorities in accordance with the provisions in the mma.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	67.	 	 	Audit api manufacturer.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	68.	 	 	Approval of component manufacturers.

	 	***
	 	***

AREA OF RESPONSIBILITY-MANUFACTURING

	 	 	 	 	 	 	 	 	 
	 	 	 	 	MANUFACTURING – RAW MATERIALS	 	WPCC	 	MEDICIS
	 	69.	 	 	Establish & approve specifications for the raw materials

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	70.	 	 	Prepare documents for change control for any matters related to the raw
materials.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	71.	 	 	Select vendor for components.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	72.	 	 	Approve vendor for components.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	73.	 	 	Procurement of components.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	74.	 	 	Procurement of API.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	75.	 	 	Inspection, testing documents, testing & release/rejection of components.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	76.	 	 	Inspection, testing documents, testing & release/rejection of API.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	77.	 	 	Retention of components raw material samples for one (1) year beyond product
expiry.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	78.	 	 	Retention of Api Raw material samples in accordance with 21 C.F.R. §211.170.

	 	***
	 	***

4

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	MANUFACTURING - PACKAGING MATERIALS	 	WPCC	 	MEDICIS
	 	79.	 	 	Artwork development, review and approval.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	80.	 	 	Establish and approve packaging specifications.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	81.	 	 	Prepare packaging specification documentation for review through change control.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	82.	 	 	Vendor selection.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	83.	 	 	Vendor approval.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	84.	 	 	Packaging materials procurement.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	85.	 	 	Inspection, inspection documents, testing & release/rejection of packaging
materials.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	86.	 	 	Notify *** of material rejections of packaging materials for *** products.

	 	***
	 	***

	 	 	 	 	 	 	 	 	 
	 	 	 	 	MANUFACTURING- BULK FORMULATION	 	WPCC	 	MEDICIS
	 	87.	 	 	Provide the specifications for product.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	88.	 	 	Prepare master manufacturing batch record.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	89.	 	 	Approve master manufacturing batch record.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	90.	 	 	Manufacture bulk products per approved specifications.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	91.	 	 	Control & review all process deviations.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	92.	 	 	Review and approve major and minor process deviations.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	93.	 	 	Establish & approve bulk product specifications.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	94.	 	 	Prepare change control bulk product specifications documentation.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	95.	 	 	Provide bulk product sampling plan.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	96.	 	 	Bulk product sampling.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	97.	 	 	Bulk product testing as per approved specification.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	98.	 	 	Review of manufacturing batch documents.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	99.	 	 	Release/rejection of bulk product for internal filling and packaging.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	100.	 	 	Approval of bulk product rejections.

	 	***
	 	***

	 	 	 	 	 	 	 	 	 
	 	 	 	 	MANUFACTURING – FILLING & PACKAGING	 	WPCC	 	MEDICIS
	 	101.	 	 	Master packaging work order preparation.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	102.	 	 	Master packaging work order approval.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	103.	 	 	Expiry date determination.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	104.	 	 	Application of lot number and expiry date to products.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	105.	 	 	Filling and packaging of released bulk products per approved packaging work
orders.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	106.	 	 	Packaging in-process line inspection and sampling.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	107.	 	 	Establish & approve finished product specifications.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	108.	 	 	Prepare finished product specifications documents.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	109.	 	 	Provide finished product sampling plan.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	110.	 	 	Finished product sampling.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	111.	 	 	Finished product testing as per approved specification.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	112.	 	 	Review of packaging batch documents.

	 	***
	 	***

	 	 	 	 	 	 	 	 	 
	 	 	 	 	MANUFACTURING – VALIDATION	 	WPCC	 	MEDICIS
	 	113.	 	 	Facility validation.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	114.	 	 	Consult with *** regarding selection of equipment used in the manufacture of
medicis products.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	115.	 	 	Approve of changes in equipment used in the manufacture of medicis products.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	116.	 	 	Manufacturing equipment validation (iq, oq, pq).

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	117.	 	 	Preparation and approval of cleaning procedures.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	118.	 	 	Cleaning validation.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	119.	 	 	Review and approve validation protocols and summary reports of validation
activities relating to the product.

	 	***
	 	***
	 	120.	 	 	Confirm that validation protocol complies with product filings.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	121.	 	 	Develop manufacturing protocol.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	122.	 	 	Validation summary report development.

	 	***
	 	***

5

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	MANUFACTURING – SHIPPING	 	WPCC	 	MEDICIS
	 	123.	 	 	Notification of special storage conditions for intermediate materials and/or
finished product.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	124.	 	 	Release/rejection of finished goods for shipping to market

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	125.	 	 	Selection of carrier for shipping and shipping conditions.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	126.	 	 	Preparation of shipping documents.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	127.	 	 	Arrangement of shipping details including, but not limited to, pick up.

	 	***
	 	***
	 	 	 	 	 
	 	 	 	 
	 	128.	 	 	Transmittal of production batch documents.

	 	***
	 	***

6

 

     Approval Signatures

     On behalf of WellSpring Pharmaceutical Canada Corp. and Medicis Manufacturing Corporation, we
agree to the conditions and relative responsibilities as set out in the above document.

	 	 	 
	 
	 

	 	 
	WellSpring Pharmaceutical Canada Corp.
	 	 
	Garnet Thompson
	 	 
	Associate Director, Quality Assurance and Compliance
	 	 
	 
	 
	 	 
	 

	 	 
	WellSpring Pharmaceutical Canada Corp.

	 	Date
	James Booker
	 	 
	Director, Quality and Regulatory Affairs
	 	 
	 
	 	 
	 
	 

	 	 
	Medicis Global Services Corporation
	 	 
	Tom Miller
	 	 
	Executive Director of Quality Operations
	 	 
	 
	 
	 	 
	 

	 	 
	Medicis Global Services Corporation
	 	 
	Terri Magee
	 	 
	Director of Quality Control
	 	 

7

 

Appendix I

PRODUCT LIST

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Laboratory*
	 	 	 	 	 	 	Packaging	 	(or noted in
	Product Code	 	Product Name	 	Dosage	 	Configuration	 	Appendix III)
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***

Appendix I

 1of 1

 

Appendix II

CONTACT LIST

	 	 	 
	WellSpring	 	Medicis
	***

	 	***
	 
	 	 
	***

	 	***

Appendix II

 1 of 2

 

Appendix II

CONTACT LIST

WELLSPRING CANADA’S PRIMARY QUALITY CONTACTS

	 	 	 	 	 	 	 
	Contact Name	 	Title	 	Telephone Number	 	e-mail
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***

MEDICIS’ PRIMARY QUALITY CONTACTS

	 	 	 	 	 	 	 
	Contact Name	 	Title	 	Telephone Number	 	e-mail
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***

Appendix II

 2 of 2

 

Appendix III

APPROVED OUTSIDE LABORATORIES

	 	 	 	 	 	 	 	 	 
	 	 	 	 	Additional Lab	 	Tests by Nucro-	 	Tests by Bodycote-
	Raw Material	 	Analytical Lab	 	Reqd?	 	Technics,	 	ORTECH Inc.
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***

	 	 	 	 	 	 	 	 	 
	 	 	 	 	Additional Lab	 	Tests by Nucro-	 	Tests by Bodycote-
	Packaging Material	 	Analytical Lab	 	Reqd?	 	Technics	 	ORTECH, Inc.
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***
	***

	 	***
	 	***
	 	***
	 	***

* ***.

Appendix III
Page 1 of 1

 

EXHIBIT C

FORM OF CERTIFICATION REQUIRED PURSUANT TO SECTION 3.5

Reference is made to that certain Master Manufacturing Agreement dated as of                                         , 20               
      (the
“Agreement”) by and between WellSpring Pharmaceutical Canada Corp. (“Supplier”) and Medicis Global
Services Corporation (“Medicis”). Capitalized terms not otherwise defined herein shall have the
meaning ascribed to such terms in the Agreement.

I,                                                             , on behalf
of and in my capacity as [title] of Supplier, do hereby certify
pursuant to Section 3.5 of the Agreement, that Supplier has the manufacturing capacity to deliver
the forecasted volumes set forth in the *** forecast delivered by Medicis pursuant to Section 3.1
of the Agreement and the monthly forecast delivered by Medicis to Supplier pursuant to Section 3.1
of the Agreement, each of which is attached hereto.

[DATE]

	 	 	 	 
	 
	 
	 	 
	 
	By:
	 	 
	Title:
	 	 

Exhibit C

Medicis/Wellspring Master manufacturing Agreement

Page 1 of 1exv10w74

Exhibit 10.74

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

CONFIDENTIAL

LICENSE AND SETTLEMENT AGREEMENT

     THIS LICENSE AND SETTLEMENT AGREEMENT (this “Agreement”) dated as of November 14, 2009 (the
“Effective Date”) is entered into between Medicis Pharmaceutical Corporation, a Delaware
corporation with an address at 7720 North Dobson Road, Scottsdale, Arizona 85256 USA on behalf of
itself and its Affiliates (collectively, “Medicis”), and Glenmark Generics Ltd., an Indian
corporation with an address at Glenmark House, HDO Corporate building, A- Wing; B.D. Sawant Marg,
Off. Western Express Highway, Chakala; Andheri — East, Mumbai- 400099 INDIA, and Glenmark Generics
Inc., USA, a Delaware corporation with an Address at 750 Corporate Drive, Mahwah, New Jersey 07430
USA, on behalf of themselves and their Affiliates (collectively, “Glenmark”).

     WHEREAS, Medicis has asserted various claims and causes of action against Glenmark in an
action captioned Medicis Pharmaceutical Corp. v. Glenmark Generics, Inc. USA and Glenmark Generics
Ltd., Case No. 09-03010 (PGS)(ES) (the “Litigation”), which is pending in the United States
District Court, District of New Jersey (the “Court”).

     WHEREAS, Medicis and Glenmark seek to resolve the Litigation without further litigation;

     WHEREAS, Medicis is the owner of the Patent Rights (as defined below); and

     WHEREAS, Glenmark desires to receive a license under the Patent Rights and Medicis desires to
grant to Glenmark a license under the Patent Rights, all on the terms and conditions of this
Agreement.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein
contained, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows:

     1. DEFINITIONS.

          1.1 “Affiliate” means, with respect to any entity, any other entity that directly or
indirectly controls, is controlled by, or is under common control with, such entity. An entity
shall be regarded as in control of another entity if it owns, or directly or indirectly controls,
at least fifty percent (50%) of the voting stock or other ownership interest of the other entity,
or if it directly or indirectly possesses the power to direct or cause the direction of the
management and policies of the other entity by any means whatsoever.

          1.2 “ANDA” means an Abbreviated New Drug Application and any supplements thereto.

          1.3 “Authorized Generic” shall mean the Generic Equivalent to the Vanos Product that is
manufactured by or on behalf of Medicis and supplied to Glenmark under the Distribution Agreement
in accordance with the terms of the Distribution Agreement provided for in Section 3.

1

 

CONFIDENTIAL

          1.4 “Bundled Products” means Authorized Generic or Generic Product, as applicable, sold or
otherwise transferred or delivered to a Third Party with one or more other products or services in
circumstances where the price of the Authorized Generic or Generic Product is either not shown
separately on the invoice, or is shown as nil (free of charge) on a separate document in relation
to the Authorized Generic or Generic Product or to a portion of the quantities of the Authorized
Generic or Generic Product.

          1.5 “Confidential Information” means all non-public materials, information and data concerning
the disclosing party and its operations that is disclosed by the disclosing party to the receiving
party pursuant to this Agreement, orally or in written, electronic or tangible form, or otherwise
obtained by the receiving party through observation or examination of the disclosing party’s
operations. Confidential Information includes, but is not limited to, information about the
disclosing party’s financial condition and projections; business, marketing or strategic plans;
sales information, customer lists; price lists; databases; trade secrets; product prototypes and
designs; techniques, formulae, algorithms and other non-public process information.
Notwithstanding the foregoing, Confidential Information of a party shall not include that portion
of such materials, information and data that, and only to the extent, the recipient can establish
by written documentation: (a) is known to the recipient as evidenced by its written records before
receipt thereof from the disclosing party, (b) is disclosed to the recipient free of
confidentiality obligations by a Third Party who has the right to make such disclosure without
obligations of confidentiality, (c) is or becomes part of the public domain through no fault of the
recipient, or (d) the recipient can reasonably establish is independently developed by persons on
behalf of recipient without the use of the information disclosed by the disclosing party.

          1.6 “FDA” means the United States Food and Drug Administration or any successor entity
thereto.

          1.7 “Fully Allocated Manufacturing Costs” or “FAMC” for Generic Product shall have the meaning
set forth in Exhibit E.

          1.8 “GAAP” shall mean generally accepted accounting principles in effect in the United States
from time to time, as consistently applied by the applicable Party with regard to their own
products and/or the standards of the industry.

          1.9 “Generic Equivalent” means ***

          1.10 “Generic Product” means ***

          1.11 “Grantback Patents” means (a) ***, (b) all divisions, continuations,
continuations-in-part, that claim priority to, or common priority with, the patent applications
described in clause (a) above or the patent applications that resulted in the patents described in
clause (a) above, and (c) all patents that have issued or in the future issue from any of the
foregoing patent applications, including utility, model and design patents and certificates of
invention, together with any reissues, renewals, extensions or additions thereto.

          1.12 “License Trigger” means, with respect to a Generic Equivalent to a Vanos Product, the
earliest of the following dates:

2

 

CONFIDENTIAL

               (a) ***;

               (b) ***; and

               (c) ***.

          1.13 “Net Profits” means ***

          1.14 “Patent Rights” means (a) the patents and patent applications listed on Exhibit A to this
Agreement, (b) all divisions, continuations, continuations-in-part, that claim priority to, or
common priority with, the patent applications described in clause (a) above or the patent
applications that resulted in the patents described in clause (a) above, and (c) all patents that
have issued or in the future issue from any of the foregoing patent applications, including
utility, model and design patents and certificates of invention, together with any reissues,
renewals, extensions or additions thereto.

          1.15 “Product” means any product for which the making, using, selling or importation is
covered by one or more claims of the Patent Rights.

          1.16 “Territory” means the United States of America, its territories and possessions,
including the Commonwealth of Puerto Rico (but excluding direct sales of Authorized Generic into
the Commonwealth of Puerto Rico).

          1.17 “Third Party” means any person or entity other than Medicis or Glenmark or their
respective Affiliates.

          1.18 “Transfer Price” shall be Medicis’ actual out of pocket acquisition cost of Authorized
Generic, the current such costs are set forth on Exhibit F (which prices will change from time to
time to reflect Medicis’ then-current acquisition costs). For the avoidance of doubt, Medicis
shall not have a duty to update Exhibit F.

          1.19 “Valid Claim” means ***.

          1.20 “Vanos Products” means the Vanos products listed on Exhibit B, as such products are
marketed and sold by Medicis as of the Effective Date in the Territory.

          1.21 “Vanos Product Patents” means (a) all patents and patent applications in the Territory
owned or controlled by Glenmark or its Affiliates heretofore or hereafter that claim or cover a
Vanos Product or Generic Equivalent or the manufacture or use of a Vanos Product or Generic
Equivalent, (b) all divisions, continuations and continuations-in-part (solely to the extent
directed to subject matter disclosed in a patent or patent application described in clause (a)
above) that (i) claim priority to, or common priority with, the patent applications described in
clause (a) above or the patent applications that resulted in the patents described in clause (a)
above and (ii) claim or cover a Vanos Product or Generic Equivalent, or the manufacture or use of a
Vanos Product or Generic Equivalent, and (c) all patents that issue after the Effective Date from
any of the foregoing patent applications, including utility, model and design patents and
certificates of invention, together with any reissues, renewals, extensions or additions thereto.

3

 

CONFIDENTIAL

     2. LICENSES; RELEASES.

          2.1 License Grant for Generic Product.

               2.1.1 Effective only upon the occurrence of the License Trigger for a Generic Product, Medicis
hereby grants to Glenmark a non-exclusive, non-transferable (except as permitted in Section 9.5)
license (without the right to grant sublicenses except to have Generic Products made on behalf of
Glenmark) under the Patent Rights to make, have made, use, offer for sale, sell and import such
Generic Products inside the Territory.

               2.1.2 Until the occurrence of the applicable License Trigger, neither Glenmark nor its
Affiliates shall, and neither shall directly or indirectly encourage or assist any Third Party to,
develop, make, use and/or commercialize any Products in the Territory.

               2.1.3 Except as expressly set forth in Section 3, nothing in this Agreement shall be construed
as creating an obligation, express or implied, on Medicis to supply any Product to Glenmark and
Glenmark shall be solely responsible for manufacturing, or having manufactured, its supply of
Generic Product.

          2.2 ***

          2.3 Grantbacks.

               2.3.1 Glenmark and its Affiliates hereby grant to Medicis a perpetual, royalty-free,
fully-paid up, non-transferable (except as provided in Section 9.5), non-exclusive license (with
the right to grant sublicenses through multiple tiers) under the Grantback Patents to make, have
made, use, offer for sale, sell and import Products in the Territory.

               2.3.2 Glenmark and its Affiliates hereby grant to Medicis a perpetual, royalty-free,
fully-paid up, non-transferable (except as provided in Section 9.5), non-exclusive license (with
the right to grant sublicenses through multiple tiers) under the Vanos Product Patents to make,
have made, use, offer for sale, sell and import Vanos Products in the Territory.

          2.4 Validity of Patent Rights.

               2.4.1 Glenmark, on behalf of itself and its Affiliates, hereby admits that the claims of the
Patent Rights are valid and enforceable. The foregoing admission regarding validity and
enforceability shall be binding upon Glenmark and its Affiliates and admissible against Glenmark
and its Affiliates in any dispute or litigation between the parties regarding the Patent Rights,
and neither Glenmark nor its Affiliates will challenge any such admission.

               2.4.2 Glenmark, on behalf of itself and its Affiliates, hereby also admits that the making,
using, offering to sell, selling, and/or importation into the Territory of a Generic Product is
covered by one or more claims of the Patent Rights under 35 U.S.C. § 271.

               2.4.3 Glenmark shall not assist any Third Party in an action to invalidate or render
unenforceable any of the Patent Rights, and Glenmark shall not disclose any of its

4

 

CONFIDENTIAL

proprietary or
confidential information relating to the validity or enforceability of any of the Patent Rights,
except to the extent required by court order or other applicable law.

               2.4.4 Glenmark shall not receive any ownership rights in the Patent Rights under this
Agreement, and Medicis shall retain the sole right, to prepare, prosecute, maintain and enforce the
Patent Rights.

          2.5 No Implied Licenses. Except as explicitly set forth in this Agreement, neither
party grants to the other party under its patents or other intellectual property any license,
express or implied. Glenmark shall not use Medicis’ name or any Medicis trademarks (including
without limitation Vanos®) in connection with the marketing, promotion or sale of any products
without the prior written consent of Medicis in each instance; provided, however, that in
connection with the Distribution Agreement Glenmark may use the Medicis tradename Vanos (but not
any associated logo or artwork) for the sole purpose of identifying the corresponding Authorized
Generic as being comparable to the applicable Vanos Product.

          2.6 Releases. In consideration of the mutual covenants herein and in the Joint
Dismissal Agreement attached hereto as Exhibit C and incorporated herein by reference, and without
limiting any remedies a party may have against the other party for a breach of this Agreement,
Glenmark hereby releases and agrees to release Medicis and Medicis hereby releases and agrees to
release Glenmark from all claims arising out of the Litigation. Upon the Effective Date, Glenmark
and Medicis shall cause to be completed, executed and filed with the Court a stipulated dismissal
with prejudice of the Litigation, in the form of the Joint Dismissal Agreement attached hereto as
Exhibit C, and to seek entry of such order by the Court. Within five (5) business days of the
execution of this Agreement, Medicis shall pay to Glenmark an amount equal to the attorneys’ fees
incurred by Glenmark in preparing for and defending the Litigation, the sum of ***.

     3. DISTRIBUTOR.

          3.1 Distribution Agreement. If, as of the License Trigger date, Glenmark has not
received approval from the FDA of its ANDA covering a Generic Equivalent, then effective as of the
License Trigger, Medicis hereby appoints Glenmark as its non-exclusive distributor of the
Authorized Generic in the Territory and authorizes Glenmark, under the Patent Rights, to
market the Authorized Generic solely to wholesalers, distributors, retailers, mail order,
managed care, and group purchasing organizations in the Territory, pursuant to a separate
distribution and supply agreement (the “Distribution Agreement”) to be entered into between
Glenmark and Medicis.

          3.2 Terms. Commencing on the License Trigger, or if the License Trigger appears to be
imminent then upon written notice by a party to the other party, the parties shall negotiate in
good faith the terms of and enter into the Distribution Agreement, which will contain the following
provisions:

               • Unless earlier terminated by either party for cause or by Glenmark for convenience,
the term of any such appointment of Glenmark as the non-exclusive distributor of the Authorized
Generic shall extend from the License Trigger and remain in effect until such

5

 

CONFIDENTIAL

time as Glenmark has
obtained approval from the FDA for its ANDA covering the Generic Equivalent, but in no event longer
than *** after the License Trigger;

                • Medicis will supply (either itself or through its Third Party manufacturer) Glenmark
*** in the Territory for the Authorized Generic in finished form; on such forecasting, invoicing,
shipment, delivery, inspection and payment terms as are agreed upon by the parties and set forth in
the Distribution Agreement;

                • Medicis will sell the Authorized Generic to Glenmark at Transfer Price;

                • Glenmark shall retain *** of all Net Sales resulting from sales of the Authorized
Generic and shall pay the remaining *** of Net Sales to Medicis, on a quarterly basis, where “Net
Sales” is defined as the amount invoiced by Glenmark in arm’s length transactions for the sale of
the Authorized Generic in the Territory to independent Third Parties in the Territory, less the sum
of the following items, all of which must directly relate to the sale and distribution of
Authorized Generic:

                    (i) trade, quantity and cash discounts and rebates;

                    (ii) any adjustments on account of price adjustments (including for example shelf stock
adjustments), rejected goods, damaged goods and returns, and product recalls;

                    (iii) credits, charge backs and prime vendor rebates, fees, reimbursements, and similar
payments actually granted or given to wholesalers and other distributors, buying groups, health
care insurance carriers, pharmacy benefit management companies, health maintenance organizations,
other institutions or health care organizations or other customers;

                    (iv) rebates or other price reductions provided, based on sales by Glenmark of Authorized
Generic, to any governmental or regulatory authority in respect of any state or federal Medicare,
Medicaid or similar programs;

                    (v) any invoiced charge for freight, insurance, handling, or other transportation costs, to
the extent specifically invoiced to the customer;

                    (vi) credits or discounts related to sales promotions and trade show discounts; and

                    (vii) any duties, sales taxes, excise taxes or other taxes imposed upon and paid by Glenmark
and not reimbursed with respect to such sales (excluding income or franchise taxes of any kind),
for all activities paid or incurred by Glenmark.

Net Sales shall be determined in accordance with the accrual method of accounting in accordance
with GAAP. Sales or transfers between or among Glenmark and its Affiliates shall be excluded from
the computation of Net Sales except where such Affiliates are end users, but Net Sales shall
include the subsequent final sales to Third Parties by such Affiliates. Bundled

6

 

CONFIDENTIAL

Products shall be
deemed invoiced at the Authorized Generic market price established by Glenmark in general
conditions of sales, or failing such general conditions, at the arm’s length price that Glenmark
would generally or in the average invoice for Authorized Generic alone. Any and all unsold
inventory, unsold product from firm purchase orders or unused in-process or excess materials and
components shall not be deducted from the Net Sales calculation.

                • Medicis and Glenmark will each indemnify the other for third party claims arising from
their actions under the Distribution Agreement and breaches of representations and warranties; and

                • such other terms as the parties may agree and as are commercially reasonable and usual
and customary for agreements of such type.

          3.3 ***

     4. FINANCIAL CONSIDERATIONS.

          4.1 Royalty.

               4.1.1 Within *** following the end of each calendar quarter during the term of this Agreement,
Glenmark shall pay to Medicis a royalty equal to *** of all *** received during such calendar
quarter for Generic Product. Medicis’s right to receive a share of the *** under this
Section 4.1.1 shall expire upon the expiration, cancellation, invalidation or abandonment
(whichever comes first) of the last Valid Claim. On the launch of a *** Generic Equivalent by a
Third Party after the Effective Date of this Agreement, for so long as there are *** Generic
Equivalents offered for sale in the Territory Glenmark shall pay to Medicis a reduced royalty at
the rate of *** of all Net Profit received.

               4.1.2 Within *** following the end of each calendar quarter during the term of this Agreement,
Glenmark shall provide to Medicis a written report stating the number and description of all
Generic Product sold during the relevant calendar quarter; the gross sales
associated therewith; the calculation of *** thereon, and the royalties that will be payable
for such calendar quarter in accordance with Section 4.1.1.

          4.2 Taxes. Glenmark shall be responsible for, and may withhold from payments made to
Medicis under this Agreement, any taxes required to be withheld by Glenmark under applicable law.
Accordingly, if any such taxes are levied on such payments due hereunder (“Withholding Taxes”),
Glenmark shall (i) deduct the Withholding Taxes from the payment amount, (ii) pay all applicable
Withholding Taxes to the proper taxing authority, and (iii) send evidence of the obligation
together with proof of tax payment to Medicis within sixty (60) days following that tax payment.

          4.3 Audit Rights. Not more than once per calendar year during the portion of the term
of this Agreement during which Glenmark shall pay Medicis royalties, on no less than thirty (30)
business days notice from Medicis, Glenmark shall make all such records, books of account,
information and data concerning (a) its sales of Generic Products pursuant to this Agreement; (b)
its manufacture of any Generic Products, and (iii) to the extent in its possession, the manufacture
of Generic Products on behalf of Glenmark by its Third Party contract

7

 

CONFIDENTIAL

manufacturer, in each case available for inspection during normal business hours by an independent auditor selected by Medicis
and reasonably acceptable to Glenmark for the purpose of an audit to determine the accuracy of the
reports delivered and amounts paid by Glenmark pursuant to Section 4.1. Medicis shall be solely
responsible for its costs in making any such audit, unless Medicis identifies a discrepancy in
favor of Glenmark in the calculation of the share of Net Profit paid to Medicis under this
Agreement in any calendar year from those properly payable for that calendar year of *** or
greater, in which event Glenmark shall be solely responsible for the reasonable cost of such audit
and pay Medicis any underpayment.

     5. TERM AND TERMINATION.

          5.1 Term. Subject to Section 5.2, this Agreement shall expire on the date when there
are no Valid Claims in the Territory; provided, however, that if there are no valid, issued patents
within the Patent Rights, but there are at such time pending patent applications within the Patent
Rights, then subject to the terms and conditions of this Agreement, the term of this Agreement
shall continue for the pendency of such pending patent applications.

          5.2 Termination for Cause. Either party may terminate this Agreement upon or after
the material breach of any material provision of this Agreement by the other party if the other
party has not cured such breach within thirty (30) days after receipt of express written notice
thereof by the non-breaching party.

          5.3 Effect of Expiration or Termination. Expiration or termination of this Agreement
shall not relieve the parties of any obligation accruing prior to such expiration or termination,
and the provisions of Sections 2.2, 2.3, 2.4, 2.6, 4.3, 5.3, 6, 8 and 9 shall survive the
expiration or termination of this Agreement.

     6. CONFIDENTIALITY.

          6.1 Confidentiality. For a period of five (5) years following the expiration or
earlier termination of this Agreement, except with respect to any Confidential Information
constituting a trade secret in which case the receiving party’s obligation continues in perpetuity,
provided such receiving party has been informed as to the status of such Confidential Information
as a trade secret, each party shall maintain in confidence all Confidential Information disclosed
by the other party, and shall not use, grant the use of or disclose to any Third Party the
Confidential Information of the other party other than as expressly permitted hereby. Each party
shall notify the other promptly upon discovery of any unauthorized use or disclosure of the other
party’s Confidential Information.

          6.2 Permitted Disclosures. Either party may disclose Confidential Information of the
disclosing party (a) on a need-to-know basis, to such party’s directors, officers and employees to
the extent such disclosure is reasonably necessary in connection with such party’s activities as
expressly authorized by this Agreement, and (b) to those agents and consultants, and contract
manufacturers who need to know such information to accomplish the purposes of this Agreement
(collectively, “Permitted Recipients”); provided such Permitted Recipients are bound to maintain
such Confidential Information in confidence at least to the same extent as set forth in
Section 6.1.

8

 

CONFIDENTIAL

          6.3 Litigation and Governmental Disclosure. Each party may disclose Confidential
Information of the other party to the extent such disclosure is reasonably necessary for
prosecuting or defending litigation, complying with a court order or applicable law, governmental
regulations or investigation, provided that if a party is required by law or regulation to make any
such disclosure of the other party’s Confidential Information it will give reasonable advance
notice to the other party of such disclosure requirement and will use good faith efforts to assist
such other party to secure a protective order or confidential treatment of such Confidential
Information required to be disclosed.

          6.4 Limitation of Disclosure. The parties agree that, except as otherwise may be
required by applicable laws, regulations, rules or orders, including without limitation the rules
and regulations promulgated by the United States Securities and Exchange Commission, the Department
of Justice and the Federal Trade Commission, or any regulations of any national securities
exchange, and except as may be authorized in Section 6.5, no information concerning this Agreement
and the transactions contemplated herein shall be made public by either party without the prior
written consent of the other.

          6.5 Publicity. Except for the press release attached hereto as Exhibit D, which both
parties shall be freely able to disclose, neither party shall make any publicity releases,
interviews or other non-confidential dissemination of information concerning this Agreement or its
terms, or either party’s performance hereunder, to communication media, financial analysts or
others without the prior written approval of the other party, which approval shall not be
unreasonably withheld, delayed or conditioned. Notwithstanding anything to the contrary in this
Agreement, the parties understand and agree that either party, may, if so required, disclose some
or
all of the information included in this Agreement or other Confidential Information of the
other party (a) in order to comply with its obligations under the law, including the United States
Securities Act of 1933 and the United States Securities Exchange Act of 1934; (b) in order to
comply with the listing standards or agreements of any national or international securities
exchange or The NASDAQ Stock Market or New York Stock Exchange or other similar laws of a
governmental authority; (c) to respond to an inquiry of a governmental authority or regulatory
authority as required by law; or (d) in a judicial, administrative or arbitration proceeding. In
any such event the party making such disclosure shall (i) provide the other party with as much
advance notice as reasonably practicable of the required disclosure, (ii) cooperate with the other
party in any attempt to prevent or limit the disclosure, and (iii) limit any disclosure to the
specific purpose at issue. In connection with any filing of a copy of this Agreement with the
Securities and Exchange Commission, the filing party shall endeavor to obtain confidential
treatment of economic and trade secret information, and shall keep the other party informed as the
planned filing (including, but not limited to providing the other party with the proposed filing
reasonably in advance of making the planned filing) and consider the requests of the other party
regarding such confidential treatment.

     7. REPRESENTATIONS AND WARRANTIES.

          7.1 Representations. Each party hereby represents and warrants to the other party
that (a) the person executing this Agreement is authorized to execute this Agreement; (b) this
Agreement is legal and valid and the obligations binding upon such party are enforceable by their
terms; and (c) the execution, delivery and performance of this Agreement does not conflict with

9

 

CONFIDENTIAL

any
agreement, instrument or understanding, oral or written, to which such party may be bound, nor
violate any law or regulation of any court, governmental body or administrative or other agency
having jurisdiction over it.

          7.2 Compliance with Law. Glenmark shall comply with all applicable laws and
regulations with respect to obtaining regulatory approval for the sale of Generic Products and its
manufacture, sale and commercialization of Authorized Generic and Generic Products. Medicis shall
comply with all applicable laws and regulations with respect to the manufacture of the Authorized
Generic.

          7.3 Disclaimer of Warranties. Except for those warranties expressly set forth in this
Agreement, neither party makes any warranty, written, oral, express or implied, with respect to
this Agreement. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE
IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT
HEREBY ARE DISCLAIMED BY BOTH PARTIES.

          7.4 Limitation of Liability. WITH THE EXCEPTION OF DAMAGES RESULTING FROM A PARTY’S
BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER THIS AGREEMENT OR ITS OBLIGATIONS UNDER SECTION 8,
OR A BREACH BY GLENMARK OF SECTIONS 2.1.2 OR 2.4, UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE
LIABLE FOR LOSS OF USE OR PROFITS OR OTHER COLLATERAL,
SPECIAL, CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT,
WHETHER SUCH CLAIMS ARE FOUNDED IN TORT OR CONTRACT.

          7.5 Equitable Relief. Glenmark acknowledges and agrees that its obligations and
undertakings under this Agreement are reasonable and necessary to protect the legitimate interests
of Medicis, that Medicis would not have entered into this Agreement in the absence of such
provisions, and that Glenmark’s threatened breach or failure to comply with Section 2.4 of this
Agreement shall cause Medicis significant and irreparable harm, the amount of which shall be
extremely difficult to estimate and ascertain, and for which money damages shall not be adequate.
Glenmark further acknowledges and agrees that Medicis shall have the right to apply to any court of
competent jurisdiction for an injunction order restraining any breach or threatened breach of this
Agreement and specifically enforcing the terms and provisions of this Agreement, without the
necessity of posting any bond or security, in addition to seeking any other remedy available to
Medicis in law or equity.

     8. INDEMNIFICATION.

          8.1 Glenmark Indemnification. Glenmark shall indemnify, defend and hold harmless
Medicis, its directors, managers, members, officers, employees, authorized subcontractors and
agents (collectively the “Medicis Indemnified Parties”) from and against any and all liabilities,
obligations, penalties, judgments, disbursements of any kind and nature, losses, damages, costs and
expenses (including, without limitation, reasonable attorney’s fees and costs) (collectively,
“Losses”) incurred as a result of any claims, demands, actions or other proceedings by a Third
Party against a Medicis Indemnified Party to the extent arising out of (a) Glenmark’s

10

 

CONFIDENTIAL

manufacture
or sale of Generic Product pursuant to this Agreement or the sale of Authorized Generic pursuant to
the Distribution Agreement; or (b) Glenmark’s breach of any representation, warranty or covenant
under this Agreement, except to the extent that such Losses arise out of Medicis’ breach of any
representation, warranty or covenant under this Agreement.

          8.2 Medicis Indemnification. Medicis shall indemnify, defend and hold harmless
Glenmark, its directors, managers, members, officers, employees, authorized subcontractors and
agents (collectively the “Glenmark Indemnified Parties”) from and against any and all Losses
incurred as a result of any claims, demands, actions or other proceedings by a Third Party against
a Glenmark Indemnified Party to the extent arising out of (a) Medicis’ manufacture of Authorized
Generic pursuant to the Distribution Agreement; or (b) Medicis’ breach of any representation,
warranty or covenant under this Agreement, except to the extent that such Losses arise out of
Glenmark’s breach of any representation, warranty or covenant under this Agreement.

          8.3 Obligations. A party which intends to claim indemnification under this Section 8
(the “Indemnified Party”) shall promptly notify the other party (the “Indemnifying Party”) in
writing of any claim, demand, action, or other proceeding in respect of which the Indemnified Party
intends to claim such indemnification; provided, however, that failure to provide such notice
within a reasonable period of time shall not relieve the Indemnifying Party of
any of its obligations hereunder except to the extent the Indemnifying Party is prejudiced by
such failure. The Indemnified Party shall permit the Indemnifying Party, at its discretion, to
settle any such action, claim or other matter. Notwithstanding the foregoing, the Indemnifying
Party shall not enter into any settlement that would adversely affect the Indemnified Party’s
rights hereunder, or impose any obligations on the Indemnified Party in addition to those set forth
herein, in order for it to exercise such rights, without the Indemnified Party’s prior written
consent, which shall not be unreasonably withheld or delayed. No such action, claim or other
matter shall be settled without the prior written consent of the Indemnifying Party, which shall
not be unreasonably withheld or delayed. The Indemnified Party shall reasonably cooperate with the
Indemnifying Party and its legal representatives in the investigation and defense of any claim,
demand, action, or other proceeding covered by the indemnification obligations of this Section 8.
The Indemnified Party shall have the right, but not the obligation, to be represented in such
defense by counsel of its own selection and at its own expense.

     9. GENERAL PROVISIONS.

          9.1 Notices. All notices hereunder shall be delivered by facsimile (confirmed by
overnight delivery), or by overnight delivery with a reputable overnight delivery service, to the
following address of the respective parties:

	 	 	 	 	 
	 

	 	If to Medicis:
	 	Medicis Pharmaceutical Corporation
	 

	 	 	 	7720 North Dobson Road
	 

	 	 	 	Scottsdale, Arizona 85256
	 

	 	 	 	Attn: Chief Executive Officer
	 

	 	 	 	Facsimile: 480-291-5175
	 
	 	 	 	 
	 

	 	with a copy to:
	 	Medicis Pharmaceutical Corporation

11

 

CONFIDENTIAL

	 	 	 	 	 
	 

	 	 	 	7720 North Dobson Road
	 

	 	 	 	Scottsdale, Arizona 85256
	 

	 	 	 	Attn: General Counsel
	 

	 	 	 	Facsimile: 480-291-8508
	 
	 	 	 	 
	 

	 	If to Glenmark:
	 	Glenmark Generics Inc., USA
	 

	 	 	 	750 Corporate Drive
	 

	 	 	 	Mahwah, New Jersey 07430
	 

	 	 	 	Attn: CEO
	 

	 	 	 	Facsimile: 201-831-0080
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Glenmark Generics Ltd.
	 

	 	 	 	Glenmark House, HDO Corporate building, A- Wing; B.D.
	 

	 	 	 	Sawant Marg, Off. Western Express Highway, Chakala;
	 

	 	 	 	Andheri — East, Mumbai- 400099 INDIA
	 

	 	 	 	Attn: CEO
	 

	 	 	 	Facsimile: 91-22-67589990

     Notices shall be effective on the day of receipt. A party may change its address listed above
by notice to the other party given in accordance with this Section 9.1.

          9.2 Entire Agreement. The parties hereto acknowledge that this Agreement sets forth
the entire agreement and understanding of the parties and supersedes all prior written or oral
agreements or understandings with respect to the subject matter hereof. No modification of any of
the terms of this Agreement, or any amendments thereto, shall be deemed to be valid unless in
writing and signed by an authorized agent or representative of both parties hereto. No course of
dealing or usage of trade shall be used to modify the terms and conditions herein. This Agreement
shall be binding on each of Glenmark and Medicis and their respective permitted successors and
assigns.

          9.3 Waiver. None of the provisions of this Agreement (including the Exhibits hereto)
shall be considered waived by any party hereto unless such waiver is agreed to, in writing, by
authorized agents of such party. The failure of a party to insist upon strict conformance to any
of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or
by law shall not be deemed a waiver of any rights of any party hereto.

          9.4 Obligations to Third Parties. Each party warrants and represents that this
Agreement does not conflict with any contractual obligations, expressed or implied, undertaken with
any Third Party.

          9.5 Assignment. Neither party shall assign this Agreement or any part hereof or any
interest herein (whether by operation of law or otherwise) to any Third Party (or use any
subcontractor) without the written approval of the other party; provided, however, that either
party may assign this Agreement without such consent (i) to any Affiliate; and (ii) in the case of
a merger, consolidation, change in control or sale of all or substantially all of the assets of the
party relating to this Agreement and the resulting entity assumes all of the obligations under this
Agreement. No assignment shall be valid unless the permitted assignee(s) assumes all obligations

12

 

CONFIDENTIAL

of its assignor under this Agreement. No assignment shall relieve any party of responsibility for the
performance of its obligations hereunder. Any purported assignment in violation of this
Section 9.5 shall be void.

          9.6 Independent Contractor. Glenmark and Medicis are acting under this Agreement as
independent contractors and neither shall be considered an agent of, or joint venturer with, the
other. Unless otherwise provided herein to the contrary, each party shall furnish all expertise,
labor, supervision, machining and equipment necessary for the performance of its obligations
hereunder and shall obtain and maintain all building and other permits and licenses required by
public authorities.

          9.7 Governing Law. In any action brought regarding the validity, construction and
enforcement of this Agreement, it shall be governed in all respects by the laws of the State of
Arizona, without regard to the principles of conflicts of laws.

          9.8 Severability. If any term or provision of this Agreement shall for any reason be
held invalid, illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall not affect any other term or provision hereof, and this Agreement shall
be interpreted and construed as if such term or provision, to the extent the same shall have been
held to be invalid, illegal or unenforceable, had never been contained herein.

          9.9 Headings, Interpretation. The headings used in this Agreement are for convenience
only and are not part of this Agreement.

          9.10 Counterparts. The Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

          8.12 No Prejudice. If at any time this Agreement is rendered null and void with
respect to the Territory or any portion thereof, or if either of Glenmark or Medicis cannot fulfill
its obligations with respect to this Agreement, it is the intent of the parties that neither party
will be in any way prejudiced with respect to its claims, causes of action, defenses and
counterclaims in the Litigation in such jurisdiction or otherwise and, except as provided herein or
therein, no consent judgment, order or dismissal entered by either party pursuant to this Agreement
in the Territory or portion thereof, as applicable, will be deemed an admission on the part of such
party.

[Remainder of this page intentionally blank]

13

 

CONFIDENTIAL

IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their
duly-authorized representatives effective as of the Effective Date.

	 	 	 	 	 	 	 
	GLENMARK GENERICS LTD.	 	MEDICIS PHARMACEUTICAL CORPORATION
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	GLENMARK GENERICS INC., USA.	 	 	 	 
	 
	 	 	 	 	 	 
	By:
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	Name:
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	Title:
	 	 	 	 	 	 
	 

	 	 	 	 	 	 

14

 

EXHIBIT A

Patent Rights

	 	 	 
	Patents

	 	Pending Applications (all U.S.)
	 

	 	 
	***

	 	***

***

A-1

 

EXHIBIT B

Vanos Products

	 	 	 
	PRODUCT	 	NDC
	Vanos (fluocinonide cream 0.1%) 30g

	 	99207-0525-30
	Vanos (fluocinonide cream 0.1%) 60g

	 	99207-0525-60
	Vanos (fluocinonide cream 0.1%) 120g

	 	99207-0525-10

B-1

 

EXHIBIT C

Joint Dismissal Agreement

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF NEW JERSEY

	 	 	 	 	 	 	 
	MEDICIS PHARMACEUTICAL CORPORATION,

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	Plaintiff,

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	v.

	 	 	)	 	 	Civil Action No. 09-3010 (PGS)(ES)
	 

	 	 	)	 	 	 
	GLENMARK GENERICS INC., USA and GLENMARK
GENERICS LTD.,

	 	 	)

)	 	 	 
	 

	 	 	)	 	 	 
	Defendants.

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
				)			

UNOPPOSED MOTION FOR ENTRY OF CONSENT JUDGMENT AND

PERMANENT INJUNCTION AS TO GLENMARK GENERICS INC., USA AND 

GLENMARK GENERICS LTD.

          Plaintiff Medicis Pharmaceutical Corporation (“Medicis”) and Defendants Glenmark Generics
Inc., USA and Glenmark Generics Ltd. (collectively, “Glenmark”) having met, conferred, and agreed
to resolve their dispute upon execution of a separate License and Settlement Agreement (“Settlement
Agreement”), Medicis respectfully moves for entry of the executed Consent Judgment and Permanent
Injunction submitted herewith. Glenmark does not oppose this motion.

B-1

 

CONFIDENTIAL

	 	 	 
	 

	 	Respectfully submitted,
	 
	 	 
	 

	 	 
	 

	 	Sheila F. McShane
	 

	 	Gibbons, P.C.
	 

	 	Attorney for Plaintiff
	 

	 	One Gateway Center
	 

	 	Newark, NJ 07102-5496
	 

	 	(973) 596-4637
	 

	 	Fax (973) 639-6482
	 

	 	SMcShane@gibbonslaw.com
	 
	 	 
	 

	 	Attorney           for           Plaintiff
	 

	 	Medicis Pharmaceutical Corporation

	 
	OF COUNSEL:

	 

	Matthew D. Powers

	Weil, Gotshal, & Manges LLP

	201 Redwood Shores Parkway

	Redwood Shores, CA 94065

	Telephone: (650) 802-3000

	Facsimile: (650) 802-3100

	 

	Nicolas G. Barzoukas

	Jason C. Abair

	Audrey L. Maness

	Weil, Gotshal, & Manges LLP

	700 Louisiana, Suite 1600

	Houston, TX 77002

	Telephone: (713) 546-5000

	Facsimile: (713) 224-9511

	 	 	 
	 

	 	 
	 

	 	Edward D. Pergament
	 

	 	Milagros A. Cepeda
	 

	 	Michael Kenney (pro hac vice)
	 

	 	Attorneys for Glenmark Generics Inc., USA and
	 

	 	Glenmark Generics, Ltd.
	 

	 	1480 Route 9 North, Suite 204
	 

	 	Woodbridge, NJ 07095
	 

	 	Tel: (732) 636-4500
	 

	 	epergament@kgplaw.com

Dated: November 13, 2009

C-2

 

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF NEW JERSEY

	 	 	 	 	 	 	 
	MEDICIS PHARMACEUTICAL

	 	 	)	 	 	 
	 CORPORATION,	 	 	)	 	 	 
	Plaintiff,

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	v.

	 	 	)	 	 	Civil Action No. 09-3010 (PGS)(ES)
	 

	 	 	)	 	 	 
	GLENMARK GENERICS INC., USA 

and GLENMARK
GENERICS LTD.,

	 	 	)

)	 	 	 
	 

	 	 	)	 	 	 
	Defendants.

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	 

	 	 	)	 	 	 
	 

	 	 	)	 	 	 

CONSENT JUDGMENT AND PERMANENT INJUNCTION

AS TO GLENMARK GENERICS INC., USA AND GLENMARK GENERICS LTD.

          This matter is before the Court on the unopposed motion of Plaintiff Medicis Pharmaceutical
Corporation (“Medicis”) and Defendants Glenmark Generics Inc., USA and Glenmark Generics Ltd.
(collectively, “Glenmark”).

          WHEREAS, this Consent Judgment and Permanent Injunction as to Glenmark concerns only
Medicis’s claims against Glenmark, and Glenmark’s counterclaims against Medicis in this Civil
Action No. 09-3010 (PGS)(ES) (referred to herein as the “Litigation”).

          WHEREAS, Medicis requests that this Consent Judgment and Permanent Injunction as to Glenmark
be entered in the above-captioned case, and Glenmark does not oppose Medicis’s request.

          WHEREAS, Medicis owns United States Patent No. 6,765,001 (the “’001 patent”) and United States
Patent No. 7,220,424 (the “’424 patent”).

C-1

 

CONFIDENTIAL

          WHEREAS, Medicis has an approved New Drug Application No. 21-758 for fluocinonide cream 0.1%,
which is sold under Medicis’s trademark Vanos®.

          WHEREAS, Glenmark Generics USA, Inc. submitted Abbreviated New Drug Application No. 91-282
(“ANDA No. 91-282”) to the FDA under 21 U.S.C. § 355(j) seeking to obtain approval to commercially
manufacture and sell generic fluocinonide cream 0.1%.

          WHEREAS, in the Litigation, Medicis alleged that Glenmark infringed the claims of the ’001 and
’424 patents under 35 U.S.C. § 271(e)(2) by Glenmark Generics USA, Inc.’s submission of ANDA No.
91-282 to the FDA.

          WHEREAS, in this Litigation, Medicis requested that a permanent injunction be issued under 35
U.S.C. § 271(e) restraining or enjoining Glenmark, its officers, agents, or attorneys and
employees, and those acting in privity or in concert with them, from engaging in the commercial
manufacture, use, offer to sell, or sale within the United States, or importation into the United
States, of any therapeutic composition, or method of use covered by the ’001 and ’424 patents for
the full term thereof, and from inducing or contributing to such activities.

          WHEREAS, Medicis and Glenmark have reached an agreement to finally settle the Litigation as
set forth in this Consent Judgment and Permanent Injunction as to Glenmark, and a separate License
and Settlement Agreement (“Settlement Agreement”) which is contemporaneously and separately being
executed.

          WHEREAS, final settlement of the Litigation serves the public interest by saving judicial
resources and avoiding the risks to each of Medicis and Glenmark associated with infringement.

          WHEREAS, final settlement of the Litigation will help Medicis and Glenmark avoid the
substantial uncertainty and risks involved with prolonged litigation.

C-2

 

CONFIDENTIAL

          WHEREAS, final settlement of this Litigation will permit Medicis and Glenmark to save
litigation costs, as well as adhere to the judicially recognized mandate that encourages the
settlement of litigation whenever possible.

          WHEREAS, Medicis and Glenmark each consent to personal jurisdiction in the District of New
Jersey for purposes of enforcing the Settlement Agreement.

          IT IS HEREBY ORDERED, DECREED, and ADJUDGED as follows:

          1. The Court has jurisdiction over Medicis and Glenmark and the subject matter of this
Litigation.

          2. Glenmark acknowledges Medicis’s ownership and standing to sue for infringement of the ’001
patent and ’424 patent.

          3. Glenmark acknowledges that the ’001 patent and ’424 patent are valid and enforceable, as
described more fully in the Settlement Agreement.

          4. Pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of any Food and Drug
Administration approval of ANDA No. 91-282 will be a date not earlier than the License Trigger, as
defined in the Settlement Agreement.

          5. Glenmark acknowledges that it has infringed the ’001 patent and the ’424 patent under 35
U.S.C. § 271(e)(2) and that Medicis did not authorize the manufacture, use, sale, offer for sale,
importation and distribution of the product described in ANDA No. 91-282.

          6. Glenmark and its affiliates are permanently enjoined as of the date hereof from infringing
the ’001 patent and ’424 patent by the manufacture, use, offer to sell, sale, importation, or
distribution of any current products, or future products having the same strength and dosage form
of the current Vanos® products, that are the subject of ANDA No. 91-282 that is not pursuant to a
license granted by Medicis, and from inducing others to infringe the ’001

C-3

 

CONFIDENTIAL

patent and the ’424 patent by inducing others to manufacture, use, offer to sell, sale,
import, or distribute any current products, or future products having the same strength and dosage
form of the current Vanos® products, that are the subject of ANDA No. 91-282 and that is not
pursuant to a license granted by Medicis.

          7. All claims and counterclaims in this Litigation are hereby dismissed without prejudice.

          8. The parties are hereby ordered to comply with the terms of the Settlement Agreement.

          9. Each party shall bear its own costs and attorneys’ fees.

          10. This Court shall retain jurisdiction over Glenmark and Medicis for the purpose of
enforcing the terms of this Consent Judgment and Permanent Injunction and over any matters related
to or arising from the interpretation or enforcement of the Settlement Agreement or any legal or
equitable claim concerning the Settlement Agreement by any third party.

IT IS SO ORDERED, DECREED AND ADJUDGED this                      day of
November, 2009 by:

	 
	 

	The Honorable Peter G. Sheridan

	United States District Judge

C-4

 

EXHIBIT D

Press Release

Glenmark Generics Inc., USA (GGI), the United States subsidiary of Glenmark Generics Limited (GGL),
announced today the settlement of all litigation pending between Glenmark and Medicis
Pharmaceutical Corporation relating to the patent actions regarding fluocinonide, the generic
version of Medicis’ Vanos® cream and ciclopirox olamine, the generic version of Medicis’ Loprox®
gel.

Under the terms of the Settlement Agreement, Glenmark will be able to market and distribute its
generic version of Vanos® cream under license from Medicis as early as December 2013, or earlier in
certain circumstances. In addition, Glenmark will have a license to launch a generic version of
Loprox® gel 0.77%, supplied by Medicis.

D-1

 

EXHIBIT E

Fully Allocated Manufacturing Costs (“FAMC”)

***

E-1

 

CONFIDENTIAL

EXHIBIT F

VANOS ACTUAL OUT OF POCKET ACQUISITION COST

	 	 	 
	30 GRAM

	 	***/EACH
	60 GRAM

	 	***/EACH
	120 GRAM

	 	***/EACH

E-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]